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This report focuses on patent landscape analysis of technologies related to vaccines targeting 
parasitic worms, also known as helminths.  These technologies include methods of formulating 
vaccines, methods of producing of subunits, the composition of complete vaccines, and other 
technologies that have the potential to aid in a global response to this pathogen.  The purpose of 
this patent landscape study was to search, identify, and categorize patent documents that are 
relevant to the development of vaccines that can efficiently promote the development of 
protective immunity against helminths. 
 
The search strategy used keywords which the team felt would be general enough to capture (or 
“recall”) the majority of patent documents which were directed toward vaccines against 
helminths.  After extensive searching of patent literature databases, approximately 2847 
publications were identified and collapsed to about 446 INPADOC families.  Relevant patent 
families, almost half of the total relevant families (210 being total number of relevant families), 
were then identified and sorted into the categories of tremetodes, cestodes, nematodes or non-
specific helminth. The 210 patent families that were divided into these four major categories 
were then further divided into sub categories relating to common fields of technology (e.g. DNA 
vaccine, vaccine formulations, methods to produce subunits) This sorting process increased the 
precision of the result set. 
 
The four major categories (cestodes, nematodes, trematodes, and non specific applications) as 
well as the overall data set of the 210 relevant family members were subjected to a range of 
analytics in order to extract as much information as possible from the dataset.  First, patent 
landscape maps were generated to assess the accuracy of the sorting procedure and to reveal the 
relationships between the various technologies that are involved in creating an effective vaccine.  
Then, filings trends are analyzed for the overall dataset of the 210 relevant families as well as by 
the categories of trematodes, cestodes, and nematodes.  The country of origin each member of 
the 210 relevant families was determined, and the range of distribution to other jurisdictions was 
assessed.  Filings were also analyzed by year, by assignee. Finally, the various patent 
classification systems were mapped to find which particular classes tend to hold helminth 
vaccine-related technologies.  Besides the keywords developed during the searches and the 
landscape map generation, the classifications represent an alternate way for further researchers to 
identify emerging helminth vaccine technologies. 
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ThemeScape map of terms from helminth vaccine patent documents.  This category contained approximately 210 
INPADOC patent families (analysis presented here is based on documents expanded from the 210 family members, 
only 751 documents were accepted by the Themespace program).  See Figure 21. 
 
The analysis included creation of a map of keywords describing the relationship of the various 
technologies involved in the development of helminth vaccines.  The map has regions 
corresponding to plasmids and other gene based technologies used in DNA vaccines for 
Japonicum Schistosoma.  Important technologies listed on the map include the use of reverse 
genetics to create reassorted viruses targeted for the use in veterinary applications. Additionally, 
the map suggests that numerous subunits exist for use in vaccines targeting cestodes, trematodes, 
and nematodes. 
 
Another major finding was that the number of patent documents related to helminths being 
published has been steadily increasing in the last decade, as shown in the figure below.  Until the 
early-1990s, there were only a few helminth vaccine related patent documents being published 
each year.  The number of publications increased noticeably when TRIPS took effect, resulting 
in publication of patent applications.  However, since 2006 the number of vaccine publications 
has exploded.  In the years 2011 and 2012, about 23 references disclosing parasitic worm 
vaccine technologies were published each year.  Thus, interest in developing new and more 
efficacious helminth vaccines has been growing in recent years.  
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Publication trends for helminth vaccine documents.  Publications increased in the 1990s when patent applications 
began to be published. See Figure 26 
 
 
The origin of the vaccine-related inventions was also analyzed.  The team determined the 
country in which the priority application was filed, which was taken as an indication of the 
country where the invention was made or where the inventors intended to practice the invention.  
By far, most of the relevant families originated with patent applications filed in the United States 
and China.  Other prominent priority countries were the United Kingdom, Japan, Brazil, 
Australia and France. Countries with the most filings were also analyzed. Countries that were 
heavily targeted for patent filings included the United States, Australia, Canada, and New 
Zealand. 
 
Top assignees for these families were mostly large pharmaceutical companies, with the majority 
of patent families coming from Heska, followed by Merck & Co., Institut Pasteur, AusBiotech 
Biotechnology, and Biological Sciences Research Council.   
 
Lastly, the jurisdictions were inventors have sought protection for their vaccine technologies 
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Jurisdictions for filing applications and issuing patents related to helminth vaccines.  Filings in multi-jurisdictional 
agencies, such as ARIPO, the Gulf Cooperation Council, WIPO and the European Patent Office, are not shown.  The 
number of patent families is out of 210 total families.  See Figure 25 for a more detailed description. 
 
 
world map shown (Fig. 25). The United States, Canada, Australia, Japan, New Zealand and 
France have the highest level of filings, followed by Germany, Brazil, India, United Kingdom 
and Spain.  However, although there are a significant number of filings in Brazil, the remainder 
of Central and South America has only sparse filings.  Of concern, with the exception of South 
Africa, few other African nations have a significant number of filings.   
 
In summary, the goal of this report is to provide a knowledge resource for making informed 
policy decisions and for creating strategic plans concerning the assembly of vaccines targeting 
highly prevalent helminth infections.  The ITTI team has defined the current state of the art of 
technologies involved in the manufacture of helminth vaccines, and the important assignees, 
inventors, and countries have been identified.  This document should aid in evaluating the 
current state of vaccines technologies targeting helminths and the potential outgrows of these 
technological fields. Furthermore, as this report illustrates, the steady increase in helminth 
patenting, expanded diversity of assignees and greater global filings, indicates that intellectual 
property protection does not inhibit the development of crucial innovations for this class of 
neglected diseases, but, on the contrary, appears to be a driver of accelerated research and 
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This educational report is neither inclusive nor comprehensive.  Rather, it is an informational 
resource intended to facilitate a better understanding of the international patent literature 
landscape regarding vaccines against helminths. 
 
This report is not a list of all potentially relevant patents.  Importantly, it is not a Freedom to 
Operate (FTO) opinion, but instead constitutes an educational analysis of potentially relevant 
material.  While the search platforms utilized in this project were extensive, none were 
comprehensive, and some countries and jurisdictions were underrepresented in the databases, 
either in the time frame covered, the availability of translated documents, and the completeness 
of the records.  Further, it is likely that the International Technology Transfer Institute (ITTI) 
team did not obtain the entire spectrum of relevant patents utilizing the various search strategies 
and methods articulated herein.  Therefore, the ITTI team does not guarantee that all relevant 
patents were discovered during the creation of this report. 
 
As the ITTI team members are not experts in the field of helminth related vaccines and related 
technologies, it is likely that the categorization of the patents found and coded are incomplete.  
Further, many patent documents contain material relevant to multiple categories; the documents 
were placed in the category that the team, in its judgment, felt best represented the overall focus 
of the document.  The ITTI team cannot guarantee that the patents discovered were evaluated at 
the level of expert scientific sophistication.   
 
The limited time frame, competing academic demands, and the general press of business dictated 
the number of patents evaluated.  As such, additional patents may have been available that were 
not considered due to time constraints. 
 
Many names are capitalized and may or may not be trademarked and/or otherwise protected 




Abbreviations and Definitions  
 
Below is a list of abbreviations and definitions for terms and keywords used throughout the ITTI 
Fall 2012 report and the reported results. 
 
Adjuvants – defined herein as a substance sometimes included in a vaccine formulation to 
enhance or modify the immune-stimulating properties of a vaccine.1 
 
Antibody – defined herein as an infection-fighting protein molecule in blood or secretory fluids 
that tags, neutralizes, and helps destroy pathogenic microorganisms (e.g., bacteria, viruses) or 
toxins.  Antibodies, known generally as immunoglobulins, are made and secreted by B-
lymphocytes in response to stimulation by antigens.  Each specific antibody binds only to the 
specific antigen that stimulated its production.2 
 
Antibody-mediated immunity – defined herein as the immunity that results from the activity of 
antibodies in blood and lymphoid tissue (also called humoral immunity).3 
 
Antigens - (immunogens; substances capable of provoking an immune response) – defined 
herein as foreign substances in the body that are capable of causing disease.  The presence of 
antigens in the body triggers an immune response, usually the production of antibodies.  
Antigens may be soluble substances, such as toxins and foreign proteins, or particulate, such as 
bacteria and tissue cells; however only the portion of the protein of polysaccharide molecule 
known as the antigenic determinant combines with antibody or a specific receptor on a 
lymphocyte.4 
 
Anti-idiotype - herein defined as a manufactured antibody (Ab2) that can recognize the idiotype 
of another antibody (Ab1).  Theoretically, the anti-idiotype antibody mimics the structure of the 
antigen recognized by Ab1.  When Ab2 is injected into the host, the host develops 
immunological memory comprising antibodies (Ab3) which have similar specificities as Ab1.5 
 
 
B cells – defined herein as small white blood cells that help the body defend itself against 
infection.  These cells are produced in bone marrow and develop into plasma cells that produce 
antibodies.  These cells are also known as B-lymphocytes.6 
 
                                                
1 American Heritage Dictionary definition: http://education.yahoo.com/reference/dictionary/entry/adjuvant.  
2 http://medical-dictionary.thefreedictionary.com/antibody.  
3 http://medical-dictionary.thefreedictionary.com/humoral+immunity.  
4 http://medical-dictionary.thefreedictionary.com/antigen.  
5 http://en.wikipedia.org/wiki/Anti-idiotypic_vaccine.  
6 http://en.wikipedia.org/wiki/B_cell.  
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BLAST – defined herein as the acronym for Basic Local Alignment Search Tool.  This 
program compares nucleotide or protein sequences to sequence databases and calculates the 
statistical significance of matches. 
 
Booster – defined herein as a second or later vaccine dose given after the primary dose(s) to 
increase the immune response to the original vaccine antigen(s).  The vaccine given as the 
booster dose may or may not be the same as the primary vaccine.7 
 
Cestode- defined herein as a member of the phyla Platyhelminths. Commonly known as a 
tapeworm. Also a member of the group called helminths.8 
 
Delivery Systems – defined herein as a method or system by which a vaccine is delivered to the 
host body.9  
 
DNA (deoxyribonucleic acid) - defined herein as the double-stranded, helical molecular chain 
found within the nucleus of each cell.  DNA carries the genetic information that encodes proteins 
and enables cells to reproduce and perform their functions.10 
 
DNA vaccine (nucleic acid vaccine) - defined herein as direct injection of a gene(s) coding for a 
specific antigenic protein(s), resulting in direct production of such antigen(s) within the vaccine 
recipient in order to trigger an appropriate immune response.11 
 
DWPI – defined herein as Derwent World Patent Index, which is the world’s most 
comprehensive database of patent documents.  DWPI includes over 20 million patent document 
families, which covers over 42.5 million patent documents.  The DWPI database includes 
coverage from over 44 worldwide patent authorities.12 
 
Efficacy - defined herein in vaccine research, the ability of a vaccine to produce a desired 
clinical effect, such as protection against a specific infection or disease, at the optimal dosage 
and schedule in a given population.  A vaccine may be tested for efficacy in Phase 3 clinical 
trials if it appears to be safe in Phase 1 trials and has shown efficacy at certain dosages in Phase 2 
trials.13 
 
                                                
7 http://en.wikipedia.org/wiki/Booster_dose.  
8 http://en.wikipedia.org/wiki/Cestoda 
9 Crystal Chan, et. al., Advancing Adjuvants and Vaccine Delivery Systems for Better Vaccination Strategies, 
BioPharm Int’l Supplements, Jan. 2, 2010. 
10 http://education.yahoo.com/reference/dictionary/entry/DNA.  
11 http://www.who.int/biologicals/areas/vaccines/dna/en/index.html.  See also http://www.dnavaccine.com/.  
12 http://thomsonreuters.com/products_services/legal/legal_products/a-z/derwent_world_patents_index/.  
13 http://en.wikipedia.org/wiki/Vaccine_efficacy.  
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Epitope - defined herein as a specific site on an antigen that stimulates specific immune 
responses, such as the production of antibodies or activation of immune cells.14 
 
Expression system - defined herein as in genetic engineering, the cells into which a gene has 
been inserted into a host cell in order to manufacture desired proteins.15 
 
Functional antibody - defined herein as an antibody that binds to an antigen and has an effect 
that can be demonstrated in laboratory tests.16 
 
Gene – defined herein as a unit of genetic material (DNA); a segment of DNA encoding a 
protein molecule; a segment of DNA that contains the information for a specific function.17 
 
Helminth- defined herein as a parasitic worm belonging to phylum nematoda or phylum 
platyhelminthies.18  
 
Host - defined herein as a plant or animal harboring another organism or a pharmaceutical 
composition.19 
 
Immune system - defined herein as the complex system (network of specialized cells and 
organs) in the host body responsible for fighting and responding to disease (immune response). 
Its primary function is to identify foreign substances (antigens of bacteria, viruses, fungi, or 
parasites) in the body and develop a defense against them.  It involves production of proteins 
called antibodies to eliminate these foreign organisms that have invaded the host, and the 
generation of cytotoxic activity to eliminate infected cells.20  
 
Immunity - defined herein as a natural or acquired resistance provided by the immune system to 
a specific disease. Immunity may be partial or complete, specific or nonspecific, long lasting or 
temporary.  Immunity is indicated by the presence of antibodies and antigen-reactive cells in the 
blood and can usually be determined with a laboratory test.21 
 
Immunization - defined herein as the process by which a person or animal becomes protected 
against a disease; the process of inducing immunity by administering an antigen (vaccine) to 
                                                
14 http://medical-dictionary.thefreedictionary.com/epitope.  
15 http://www.news-medical.net/health/Gene-Expression-System.aspx.  
16 http://en.wikipedia.org/wiki/Antibody.  
17 http://en.wikipedia.org/wiki/Gene.  
18 http://www.who.int/topics/helminthiasis/en/; see also, http://www.phsource.us/PH/PARA/Chapter_4.htm 
19 http://en.wikipedia.org/wiki/Host_%28biology%29.  
20 http://en.wikipedia.org/wiki/Immune_system.  
21 http://medical-dictionary.thefreedictionary.com/immunity.  
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allow the immune system to prevent infection or illness when it subsequently encounters the 
infectious agent.  This term is often used interchangeably with vaccination or inoculation.22 
 
INPADOC (International Patent Document Center) – defined herein as a patent database 
maintained by the European Patent Office (EPO).23 
 
ITTI – defined herein as International Technology Transfer Institute, an intellectual 
property clinic at the University of New Hampshire School of Law.24 
 
NCBI – defined herein as the acronym for National Center for Biotechnology 
Information. NCBI provides access to biomedical and genomic resources, such as BLAST.25 
 
Nematode- defined herein as a member of the phylum nematoda, common specimens of 
nematodes include roundworms, whipworms, and threadworms.26 
 
Parasitic Worm- defined herein as a member of the phyla Nematoda or plathyhelminthies. Also 
known as a helminth.  
 
Passive immunization – defined herein as the introduction of antibodies or antiserum into a host 
to treat an infection, wherein such treatment does not result in immunological memory and long-
lasting immunity in the host.27 
 
Patent document count – defined herein as an expanded patent family which includes all issued 
patents and patent applications that fall within that family.  
 
Patent family – defined herein as a group of patent documents having a commonality such as 
priority document (INPADOC) or claimed invention (DWPI).  The patent documents can be 
from any jurisdiction. 
 
PCT – defined herein as the Patent Cooperation Treaty, which is an international treaty 
whose goal is to provide a unified procedure for filing patent applications in the contracting 
states.  A contracting state is a country which has signed onto the treaty.  A patent application 
filed under the PCT is commonly referred to as an international application, or PCT 
application.28 
 
                                                
22 http://www.who.int/topics/immunization/en/.  
23 http://www.epo.org/searching/essentials/patent-families/inpadoc.html.  
24 http://law.unh.edu/franklin-pierce-ip-center/international-technology-transfer-institute.  
25 http://www.ncbi.nlm.nih.gov/.  
26 http://en.wikipedia.org/wiki/Nematode 
27 http://en.wikipedia.org/wiki/Passive_immunity.  
28 http://www.wipo.int/pct/en/texts/articles/atoc.htm.  
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Pharmaceutical Compositions – defined herein as the combination of distinct parts or elements 
to form a whole relating to pharmacy, drugs, or medicine.  This can include anything from 
vitamins, antibodies, antigens, medicaments, and adjuvants. 
 
Trematoda- defined herein as a subphyla of phylum platyhelminthies. This phylum contains one 
of the most commonly known helminth, liver flukes.29  
 
Vaccine - defined herein as a preparation that stimulates an immune response that can prevent an 
infection or create resistance to an infection based upon an antibody response to an antigen.30 
 
Veterinary Vaccines- herein defined as vaccines targeting helminths for the specific use in non-






























                                                
29 http://en.wikipedia.org/wiki/Trematode  
30 http://en.wikipedia.org/wiki/Vaccine.  
31 http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=1731.  
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Background of the Technology 
 
Parasitic worms, also known as helminths are worm-like organisms that live in and feed 
on living hosts. These parasitic worms are multicellular 
organisms that are generally visible to the naked eye in their 
adult stages.32 Parasitic worms general fall into three different 
phyla: plathyhelminthies or flatworms, acanthocephia or thorny 
headed worms, and nematoda or roundworms.33 This report 
focuses on parasitic worms that are from the phyla nematoda and 
platyhelminths and not those from the phyla acanthocephia.  
The phylum plathyhelminths, also known as flatworms, is 
a diverse phylum that contains cestodes (tapeworms), trematodes 
(flukes) and tubellaria. The class tubellaria will not be included 
in this report as they do not infect humans. The term cestode is 
derived from the Latin word cestus, which means "tape". The 
adult forms of all 3,400 species of cestodes are internal parasites 
in the organs of vertebrates, including fish, cats, dogs and 
humans.34 Cestodes have no mouths as their syncitial skin 
absorbs nutrients from their host. This syncitium also disguises 
these nutrients chemically chemically to avoid attacks by the 
host's immune system.35   
 Class trematoda, individuals of this class known as 
trematodes, contains the organism known as flukes, one of the most well 
known and most prevalent helminths to infect humans.36 The term 
trematoda refers to the cavities in their holdfasts, which resemble a 
sucker of leech, and anchors them within their host.37 The skin of all 
trematodes is composed of a syncitium, a layer of cells that shares a 
single external membrane. The class trematoda contains more than 11,000 unique species, 
making it one of the most prevalent types of parasitic worms on earth. 
The last phyla of interest is nematoda, members of this phylum are also known as 
roundworms. Phylum nematoda is one of the largest groups of animals as over two thousand 
eight hundred species are contained in this phylum38 Species from phylum nematoda inhabit 
                                                
32 Maizels RM, Yazdanbakhsh M, "Immune regulation by helminth parasites: cellular and molecular 
mechanisms". Nat. Rev. Immunol. 3 (9): 733–44. (2003)  
33 Ibid 
34 Ruppert, E.E., Fox, R.S., and Barnes, R.D. (2004).Invertebrate Zoology (7 ed.). Brooks / Cole. pp. 226–269. 
35Ibid 
36 Ibid. 
37 Ibid.  
38 Hugot J-P, Baujard P, Morand S (2001). "Biodiversity in helminths and nematodes as a field of study: an 
overview". Nematology 3 (3): 199–208 
Figure 1. An image depicting 
phyla nematoda and 
platyhelminthies relationship 
to other phyla.  
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almost every ecosystem known to man.39 Nematodes vary greatly in size as some may be as long 
as 5cm while others may be microscopic in size.40 Unlike the group platyhelminthies, nematodes 
outer covering may be either a syncitum or a thick nonliving cuticle layer.41 
 
 
Helminth Life Cycles, Diseases, and Epidemiology 
 
Approximately one billion people in the poor, developing regions of sub-Saharan Africa, 
Asia, and the Americas are infected with one or more parasitic helminth. 42 The most common 
helminth diseases are caused by an infection from soil-transmitted nematodes (e.g. the 
roundworm), filarial worms, flukes, or tapeworms (See Table 1). Many of the people living in 
poor rural villages in the tropics and subtropics are often chronically infected with several 
different species of parasitic worm, commonly referred to as “polyparasitized”.43 Note that the 
above table is from 2008 and that the prevalence for some helminths have decreased and 
increased remarkably. More accurate statistics will be further reflected in the report. 
 
 
Figure 2. Major human helminthiases and their global prevalence and distribution44 
                                                
39  Borgonie G, García-Moyano A, Litthauer D, Bert W, Bester A, van Heerden E, Möller C, Erasmus M, Onstott 
TC (June 2011). "Nematoda from the terrestrial deep subsurface of South Africa". Nature 474 (7349): 79–82. 
40 Ruppert EE, Fox RS, Barnes RD (2004). Invertebrate Zoology (7th ed.). Brooks/Cole. 
41 Ibid. 
42 Hotez, Peter, Paul Brindley, Jeffrey Bethony, Charles King, Edward Pearce, and Julie Jacobson. "Helminth 
infections: the great neglected tropical diseases." The Journal of Clinical Investigation 118, no. 4 (2008): 1311.  
43 Ibid. 
44 Ibid. at 1312. 
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There are four primary modes of helminth transmission: soil-borne, foodborne, water-
borne, and insect-borne. Most of the diseases WHO determined neglected tropical diseases are 
soil-borne.45 Environmental factors, such as warm, moist climates and poor sanitation and 
hygiene, make tropical areas the perfect habitat for soil-borne helminths, however, many species 
may survive in temperate climes, as well, especially during the summer. In Latin America and 
the Caribbean, soil-transmitted helminths are present in all countries with an estimated 26.3 
million school-age children at risk of infection. In 13 of the 14 countries in this region, many 
areas have infection prevalence higher than 20%. Globally, approximately 300 million people 
suffer from severe morbidity that results in 10,000–135,000 deaths annually. However, their 
greatest impact is through the impairment of physical and mental development in children, which 
ultimately retards educational advancement and economic productivity. 46 
A study of detailed description of the global limits for Ascaris lumbricoides, Trichuris 
trichiura, and the hookworms Ancylostoma duodenale and Necator americanus using surveys of 
infection prevalence derived from the Global Atlas of Helminth Infection.47 Figure 1 shows the 




Figure 3. Distribution of soil-transmitted helminth indicating areas at stable risk of transmission in 201048 
  
 Based on factors such as climatic and socio-demographic indicators, human population 
density and settlement patterns, it was estimated that “5.08 billion people (1.0 billion of school-
going age) live in areas of stable hookworm transmission worldwide, 22% located in Africa and 
                                                
45 World Health Organization. "Neglected Tropical Diseases." WHO Programmes and Projects. 
www.who.int/neglected_diseases/diseases/en/ (accessed February 25, 2013). 
46 Ibid. 
47 Pullan, Rachel, and Simon Brooker. "The global limits and population at risk of soil-transmitted helminth 
infections in 2010." Parasites and Vectors 5, no. 81 (2012): 2. 
48 Ibid. at 11. 
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the Middle East, 69% in Asia and 9% in Latin America and the Caribbean”.49  
Generally, soil-borne worm eggs or juveniles contaminate soil via animal and human 
defecation or the use of feces containing such eggs or juveniles as fertilizer for produce. The 
eggs are ingested via contaminated produce or by placing fingers or other objects that have come 
into contact with contaminated soil into one’s mouth.  Usually there is no vector which the egg 
or juvenile must pass through and mature in before infecting the terminal host.  
Because most soil-borne worms primarily infect the small and large intestine, individuals 
parasitized by different species of these worms often present with a similar set of gastrointestinal 
symptoms.   
Ascaris lumbricoides is one of the most 
prevalent of the prevalent, accounting for a large 
percentage of the global parasitic worm burden.50 
The CDC estimates that 807-1,221 million people 
worldwide are infected by this species. The 
ascarid lifecycle is unique from other soil-borne 
worms in that the larvae must mature in the lungs. 
Eggs are ingested and hatch in the gastrointestinal 
tract from which they burrow through the mucosa 
to the portal veins leading to alveoli and 
pulmonary vascular capillary beds.51 The larvae 
cause lung irritation which results in the host 
coughing the larvae up into the oral cavity where 
they are swallowed back down into the GI tract. 
52The female can release 200,000 eggs each day.  
Adults live for a year or two.     Figure 4. Lifecycle of A. Lumbricoides 
Ascariasis is more burdensome for children, and can be transmitted to a fetus 
transplacentally. Annually, there are 8-100,000, most of which are children with obstructed or 
perforated bowels. Along with the GI symptoms common to all intestinal worms, ascariasis can 
also present with wheezing, intestinal blockage, tingling throat, appendicitis, pancreatitis, and 
impaired growth in children.53 
 
                                                
49 Pullan, Rachel, and Simon Brooker. "The global limits and population at risk of soil-transmitted helminth 
infections in 2010." Parasites and Vectors 5, no. 81 (2012): 10.  
50 Centers for Disease Control and Prevention. "CDC - Ascariasis." Centers for Disease Control and Prevention. 
http://www.cdc.gov/parasites/ascariasis/index.html (accessed May 9, 2013). 
51 Medscape Reference. "Ascaris Lumbricoides." Drugs, Diseases, & Procedures. 
emedicine.medscape.com/article/788398-overview (accessed May 9, 2013). 
52 Centers for Disease Control and Prevention. "CDC - Ascariasis." Centers for Disease Control and Prevention. 
http://www.cdc.gov/parasites/ascariasis/index.html (accessed May 9, 2013). 
53 Medscape Reference. "Ascaris Lumbricoides." Drugs, Diseases, & Procedures. 
emedicine.medscape.com/article/788398-overview (accessed May 9, 2013). 
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Hookworms are estimated to infect 
between 760 million-1.3 billion people 
worldwide.54 Two main species, 
Anclostoma duodenale and Necator 
americanus, are responsible for the 
global worm burden.  Hookworm 
infection is widespread throughout the 
tropics and subtropics.  N. americanus is 
the most prevalent hookworm, being 
found throughout sub-Saharan Africa, 
tropical regions of the Americas, south 
China, and Southeast Asia while A. 
duodenale is spreading in parts of India,  
China, Africa, and parts of the Americas.55            Figure 5. Lifecycle of the hookworm 
The eggs of these species are not infectious. The eggs are released into the soil in feces, 
where they mature into larvae. Unlike other soil-borne helminths, an individual becomes infected 
when a larva penetrates one’s bare feet. A. duodenale larvae are infectious if ingested, while this 
is not the case for N. americanus.     
Ancylostomiasis is often symptomless if the parasite burden is low. A higher burden 
presents with anemia and fatigue, along with GI symptoms. Because children and women of 
reproductive age have reduced iron reserves, both are at particular risk. In children, anemia and 
protein malnutrition resulting from chronic intestinal parasitism can cause impairment in 
physical, intellectual, and cognitive development.  In pregnant women, severe iron deficiency 
anemia arising from hookworm disease can result in additional health risks for the mother and 
fetus or newborn. 56 
                                                
54 Lustigman, Sara, Roger Prichard, Andrea Gazzinelli, Warwick Grant, Boakye Boatin, James McCarthy, and 
Maria Basanez. "A Research Agenda for Helminth Diseases of Humans: The Problem of Helminthiases." PLoS 
neglected tropical diseases 6, no. 4 (2012): 4. 
55 Ibid. 
56 Ibid at 283. 
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Figure 6. Prevalence of hookworm infection worldwide 57 
 
Food-borne helminths are transmitted through ingestion of undercooked meat (including 
fish, mammals, and mollusks), raw 
aquatic plants, and raw vegetables 
contaminated by fecal matter. Poor 
hygiene, unsanitary food preparation 
and undercooking are the leading 
factors of transmission. Diseases caused 
by foodborne helminths have common 
symptoms: abdominal pain, diarrhea, 
muscle pain, cough, lesions, 
malnutrition, weight loss, and 
neurological deficiencies.58  
Trichinella spiralis is a 
nematode that requires two intermediate 
hosts. The worm initially infects a 
rodent, which is then eaten by a pig or 
another carnivore. A human ingests 
undercooked pork containing encysted 
 larvae. Encysting allows the larvae to    Figure 7. Lifecycle of T. spiralis 
remain dormant for years while waiting  
                                                
57 Ibid. at 284. 
58 "CDC - Parasites - Food." Centers for Disease Control and Prevention. http://www.cdc.gov/parasites/food.html 
(accessed May 9, 2013). 
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to be transmitted to a terminal host.  Gastric acid and pepsin in the host stomach degrade the cyst 
and allow the release of the larva.  The larvae mature in the small intestine, where they live for 
about 4 months.59 
Trichinella can be found in almost every corner of the world. Other species of Trichinella 
infect different hosts and may also infect humans. T. pseudospirals infects mammals and birds, 
however, it does not encyst in the striated muscle like T. spiralis. T. native infects arctic bears. T. 
nelson infects African predators and scavengers. T. brivovi     
infects European and Asian carivores.60            
The severity of the symptoms of trichinellosis (or trichinosis) is correlated to the worm 
burden of the afflicted host. If the burden 
is low, the host may be asymptomatic or 
presenting with mild gastric symptoms 
like nausea and diarrhea. Mild cases tend 
to mirror the flu and clear up on their own 
within a few months. Severe infection can 
result in difficulty coordinating 
movements, cardiac and pulmonary 
problems, and even death.61 
Diphyllobothrium is transmitted 
through fish and is found in Europe, Asia, 
Russia, North America, Uganda, and 
Chile. This tapeworm has become an 
increasingly global problem as infected  
Figure 8. Lifecycle of Diphyllobothrium 
 
fish are sold on the world market. Luckily, this tapeworm is killed by properly cooking or 
freezing the infected fish. Fish become infected after eating an infected copepod.  The mature 
adults live in the small intestine of humans. A female has over 3, 000 gravid proglottids-where 
each proglottid is capable of releasing huge numbers of eggs-resulting in around a million eggs 
released per worm each day. There are several species of Diphyllobothrium. D. latum is the 
largest and can grow up to 30 feet in length.62 
Diphyllobothriasis is usually asymptomatic and can go years without detection.  In severe 
cases, the host may suffer intestinal obstruction, gall bladder disease caused by migrating 
proglottids, the common GI symptoms noted above.  Severe vitamin B12 deficiency may occur 
                                                
59 "CDC - Trichinellosis." Centers for Disease Control and Prevention. http://www.cdc.gov/parasites/trichinellosis/ 
(accessed May 9, 2013). 
60 Ibid. 
61 Ibid. 
62 "CDC - Diphyllobothrium." Centers for Disease Control and Prevention. 
http://www.cdc.gov/parasites/diphyllobothrium/ (accessed May 9, 2013). 
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after years of infection, as the parasite absorbs approximately 80% of the hosts B12. Subacute 
degeneration of the spinal cord also occurs in more severe cases.63 
Taenia sp. are cestodes found in Latin 
America, Asia, and Africa.64 Some of the 
prevalence of this parasite in developed 
countries is because of immigration from and 
tourism. 65Humans are their only terminal host. 
Cows are the vectors for T. saginata. Pigs are 
the vectors for T. solium. Poor sanitation and 
improper food preparation lead to human 
infection when humans eat undercooked 
contaminated pork or beef. Gravid proglottids 
containing eggs are released in feces and 
remain infective for months in moist 
environments. Cattle and pigs are infected after 
eating contaminated vegetation. Oncospheres 
hatch from the eggs in the vector’s          Figure 9. Lifecycle of  Taenia 
intestine. The oncospheres invade the intestinal wall and migrate to the striated muscle where 
they encyst as cysticerci, which can survive dormant for years. A human eats this undercooked 
meat. Adults attach to the small intestine. Six gravid proglottids are released in feces each day, 
with each proglottid containing hundreds of thousands of eggs.66 
Taeniasis can be asymptomatic when acute.  T. saginata tends to be more symptomatic 
than T. solium. In more serious infections the host experiences abdominal pain, appetite loss, 
weight loss, upset stomach. Proglottids may get stuck in appendix, or in the biliary or pancreatic 
ducts. T. solium can cause cysticercosis, an infection of the brain, muscle and other tissues by 
cystircerci. Symptoms include seizures, muscle and eye damage. 67   
Flukes are a type of trematode that infect 56 million people in 70 countries. All members 
of this group have similar life cycles, with the exception of schistosomes, which will be covered 
in waterborne worms below.  
Clonorchis sinensis is a liver fluke found primarily in Asia. It infects does and fish eating 
carnivores. Eggs are released with feces. They require freshwater to develop into cercaria. The 
                                                
63 "CDC - Diphyllobothrium." Centers for Disease Control and Prevention. 
http://www.cdc.gov/parasites/diphyllobothrium/ (accessed May 9, 2013). 
64 64 "CDC - Taeniasis." Centers for Disease Control and Prevention. http://www.cdc.gov/parasites/taeniasis/ 
(accessed May 9, 2013). 
 
65Lustigman, Sara, Roger Prichard, Andrea Gazzinelli, Warwick Grant, Boakye Boatin, James McCarthy, and Maria 
Basanez. "A Research Agenda for Helminth Diseases of Humans: The Problem of Helminthiases." PLoS neglected 
tropical diseases 6, no. 4 (2012): 4. 
66 "CDC - Taeniasis." Centers for Disease Control and Prevention. http://www.cdc.gov/parasites/taeniasis/ (accessed 
May 9, 2013). 
67 Ibid. 
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cercaria is eaten by a snail, where it matures into a metacercaria. The metacercaria leaves the 
snail and penetrates a fish, encysting in the subcutaneous tissue. That fish is eaten by a carnivore. 
The metacercaria is released from the cyst in the host’s intestine, whence it migrates to the bile 
ducts.68 
 Clonorchiasis affects 12.5 
million people in China alone. An 
acute infection may be asymptomatic. 
More severe infections cause fever, 
pain in the upper right quadrant, colon 
pain, gall bladder obstruction. 
Chronic infection destroys the liver 
parenchyma and causes inflammation 
of the walls of the bile ducts, resulting 
in fibrosis. Fibrosis of the bile ducts 
puts the host at risk for 
cholangiocarinoma, which is severe 
and often fatal bile duct cancer.69  
         Figure10 . Lifecycle of the Fluke. 
 
Fasciola hepatica and Fasciola gigantica are local to Europe, the Americas, Oceania and 
especially the South American highlands. Greater incidences of infection are found along trade 
routes of the host plants, watercress and water mint. Other hotspots for infection include the Nile 
valley, Caspian Sea basin, as well as East and Southeast Asia. 2.4 million People are infected in 
over 70 countries. The worms contaminate a freshwater source when an infected animal 
defecates in or near that source. Cercariae hatch from the eggs and penetrate snails. The cercariae 
mature into metacercariae and leave the snail. The metacercariae affix themselves to an aquatic 
plant and form metacercarial cysts. Humans are infected either by eating the plant or an animal 
that has eaten the plant, or by imbibing water with free floating metacercarial cysts. In the human 
host, metacercariae penetrate the intestinal wall and peritoneum to get to the liver, which they 
burrow through on their way to the bile ducts. Metacercariae mature into adults in the bile ducts 
and then release eggs into the bile which flows to the intestine and out with feces.70  
Fascioliasis is asymptomatic in the acute phase. After two to four months, the host suffers 
internal bleeding (due to migration of the metacercaria), fever, nausea, swollen liver, skin rashes, 
and severe abdominal pain. Once the metacercariae reach the bile ducts the host suffers 
                                                
68 "CDC - Clonorchis - Biology." Centers for Disease Control and Prevention. 
http://www.cdc.gov/parasites/clonorchis/biology.html (accessed May 9, 2013). 
69 World Health Organization. "Clonorchiasis." Foodborne Trematode Infection. 
www.who.int/foodborne_trematode_infections/clonorchiasis/en/ (accessed February 25, 2013). 
70 World Health Organization. "Fascioliasis." Foodborne Trematode Infection. 
www.who.int/foodborne_trematode_infections/clonorchiasis/en/ (accessed February 25, 2013). 
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intermittent pain, jaundice, anemia, pancreatitis, gallstones, and liver fibrosis due to prolonged 
inflammation. Secondary infection often occurs.71  
Waterborne helminths are transmitted through contact with water either via imbibition or 
physical contact.72  
Drancunculus medinensis, or the 
Guinea worm, is transmitted to humans 
when a human drinks water containing 
infected copepods. The copepods die in the 
GI tract and release larvae. The larvae 
penetrate the host’s stomach or intestinal 
wall and migrate to the abdominal cavity and 
retroperitoneal space, where they mature into 
adults. After copulating the male dies and the 
female migrates to the subcutaneous tissue of 
a lower extremity. After a year of living in 
the subcutaneous tissue, a blister forms 
around the worm. When the blister ruptures, 
the female emerges and releases larvae upon 
contact with water. Those larvae are eaten by                         Figure 11. Lifecycle of the Guinea Worm 
copepod, in which they molt twice before  
becoming infective to humans.73 
 A human with dracunculiasis, or Guinea worm disease, remains asymptomatic for 
approximately a year while the worm is maturing, mating, and migrating.74Once the worm is 
ready to release larvae, the host may suffer from blisters, ulcers and edema which cause a 
burning pain that the host tries to alleviate by dipping the lesion in cool water.75 These symptoms 
are accompanied by itchy rashes, fever, nausea, vomiting, diarrhea, and dizziness.76 It is common 
for the host to suffer secondary infection due to exposure of lesion. In that case, the host may 
suffer cellulitis (redness and swelling of the skin), abscesses, sepsis, septic arthritis-infections of 
the joints that may lead to deformation of the joints, and tetanus. The disease is treated by 
wrapping the worm around a rod and turning that rod a little bit every day to remove the worm 
without breaking it. Breaking the worm causes inflammation and painful cellulitis where the 
                                                
71 Ibid 
72 "CDC - Parasites - Water." Centers for Disease Control and Prevention. http://www.cdc.gov/parasites/water.html 
(accessed May 9, 2013). 
73 "CDC - Guinea Worm." Centers for Disease Control and Prevention. http://www.cdc.gov/parasites/guineaworm/ 
(accessed May 9, 2013). 
74 Ibid 
75 World Health Organization. "About Guinea Worm Disease." Dracunculiasis. 
www.who.int/dracunculiasis/disease/en/ (accessed February 25, 2013). 
76 "CDC - Guinea Worm." Centers for Disease Control and Prevention. http://www.cdc.gov/parasites/guineaworm/ 
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worm degrades. This disease causes lack of mobility for 2 months or more and can cause 
permanent disability in children.77  
 The number of new cases of dracunculiasis occurring worldwide each year has decreased 
from an estimated 3.5 million to 1,058 since the 1986 World Health Assembly, the decision-
making body of the World Health Organization, declared global elimination as a goal.78  The 
number of dracunculiasis cases reported worldwide in 2011 declined by 41%, compared with 
2010, and by 51% from January–June 2011 to January–June 2012. Transmission remains 
endemic in four countries, with just one, South Sudan, accounting for 99% of all reported cases 























Figure 12. Geographical distribution of co-infections with helminth infections.  Infections include: lymphatic 
filariasis (LF), onchocerciasis (Oncho), schistosomiasis (SCH), and soil-transmitted helminthiases (STH). 80 
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Report, October 26, 2012.  
79 Ibid. 
80 Lustigman, Sara, Roger Prichard, Andrea Gazzinelli, Warwick Grant, Boakye Boatin, James McCarthy, and 
Maria Basanez. "A Research Agenda for Helminth Diseases of Humans: The Problem of Helminthiases." PLoS 
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Schistosomes are known as the blood flukes.81 This trematode is the cause of widespread 
infection in 76 countries and territories. Schistosoma mansoni is endemic in 54 countries and S. 
haematobium in 55. Infection by S. japonicum remains an important public health burden in the 
Philippines, China, and parts of Indonesia, despite the program controls taking place. Almost 800 
million individuals are at risk across the globe; about 200 million people are infected. Of the 200 
million people infected with Schistosoma spp. in the world, 160 live in SSA, where 
approximately 110 million are infected with S. haematobium. Schistosomiasis causes “15,000–
280,000 deaths annually in SSA alone and severe disability in approximately 20 million 
people”.82  
Schistosome eggs are passed in feces or urine and hatch in water. The larvae penetrate a 
snail in which they mature into an infective stage larvae. These infective larvae are released back 
into the water, where they can survive for up to two days while waiting to encounter a host. 
When a human steps into the 
contaminated water the 
schistosome larva penetrates 
the skin on the individual’s 
foot. From the foot the larva 
migrates through the tissues 
to the veins.83 Adults live in 
the mesenteric venules 
emptying into the unrinary 
tract, intestine and 
abdominal cavity. Eggs often 
get trapped in the body 
causing tissue damage.84  
 Schistosomiasis is 
known in some parts of the 
world as bilharzia. The host 
is initially asymptomatic. A 
few days after infection the 
host develops an itchy rash. 
After a month or two fever,                            Figure 13. Lifecycle of a Schistosome 
chills, cough and muscle ache set in. Years of infection causes damage to the liver, intestine, 
spleen, lungs and bladder. 200,000 cases a year result in death in sub-Saharan Africa. There are 
two types of schistosomiasis: intestinal and urogenital. Intestinal schistosomiasis causes 
                                                
81 World Health Organization. "Schistosomiasis." Programmes and Projects. 
www.who.int/schistosomiasis/en/index.html (accessed February 25, 2013). 
82 Ibid. at 5. 
83 Ibid 
84 World Health Organization. "Schistosomiasis." Programmes and Projects. 
www.who.int/schistosomiasis/en/index.html (accessed February 25, 2013). 
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abdominal pain, enlarged liver, bloody stool, diarrhea and enlarged spleen. Urogential 
schistosomiasis causes difficulty urinating, heightened risk of bladder cancer, bloody urine, 
infertility and bladder and ureteral fibrosis. Urogenital schistosomiasis can cause infertility in 
both men and women. Women may suffer from lesions on the cervix or vagina, vaginal bleeding, 
nodules on the vulva, and pain during intercourse. Men may suffer damage to the seminal 
vesicles and prostate. Eggs released by schistosomes that inadvertently migrate to the brain or 
spinal cord cause seizures, paralysis and inflammation of the spinal cord. Children are especially 
susceptible to anemia, malnutrition and learning disabilities. Different species are correlated with 
certain types of cancer and fibrosis.85  
Insect-borne are transmitted to humans when the insect-vector bites a human. 
Onchocerca volvulus is prevalent in fertile riverside areas where Simulium blackflies live. An 
infected fly bites a human, passing the larvae to the subcutaneous tissue. The larva creates a 
nodule, where it matures into an adult. The female releases around 1,000 juveniles a day. The 
juveniles migrate to the subepidermal tissue so that they may be transmitted to a fly when the 
human is bitten.86 
 Onchocerciasis, also known as River Blindness, has rendered around half a million 
people blind and is the leading cause of blindness in west and central Africa. The disease is also 
prevalent in 6 Latin American countries. Presently, it is estimated that 37 million people carry O. 
volvulus, with 90 million at risk in Africa. Morbidity at present is estimated at 987,000 disability-
adjusted life-years and there are 46,000 new cases of blindness annually.87 See Figure 13. 
Onchocerciasis causes skin rashes and lesions, intense itching and depigmentation, as 
well as optical symptoms. The eye may be inflicted with bleeding, lesions and inflammation. 
Every part of the eye is subject to infection, except the lens, however the lens may still become 
inflamed. These symptoms cause blindness.88  
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86 "World Health Organization, “Prevention of Blindness and Visual Impairment: Onchocerciasis." Programmes and 









Wucheria bancrofti is transmitted through mosquito bites. The larva migrate to lymphatic 
vessels after transmission and mature into adults.90 The resulting disease is lymphatic filariasis, 
which is endemic in 83 countries and territories. It is 
estimated that 1.3 billion people are at risk for 
developing the disease, with some 120 million people 
being infected. Over 40 million people are seriously 
incapacitated and disfigured by the disease. Of these, 
95% are infected with Wuchereria bancrofti, and the 
remainder with Brugia malayi or Brugia timori. The 
infection, usually acquired in early childhood, causes 
considerable morbidity and social stigma because of 
the deformities it produces.91. Lymphedema, or 
pooling of lymphatic fluid in the extremities, occurs in 
the early stages of this disease. Late stage lymphatic 
filariasis results in elephantiasis.92 
             Figure 15. Lifecycle of W. bancrofti 
                                                
89 Ibid. at 1381. 
90 World Health Organization. "Lymphatic Filariasis." Programmes and Projects. 
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91 Lustigman, Sara, Roger Prichard, Andrea Gazzinelli, Warwick Grant, Boakye Boatin, James McCarthy, and 
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Types of Vaccines 
The types of vaccines encountered are divided into protein subunit vaccines and DNA 
vaccines. Protein vaccines formed by introducing a fragment of microorganism to the immune 
system to create an immune response.93  Examples include the subunit vaccine against Hepatitis 
B virus that is composed of only the surface proteins of the virus.94 
DNA vaccines employ modified DNA that is injected into the cells of the body, where 
the "inner machinery" of the host cells "reads" the DNA and uses it to synthesize the pathogen's 
proteins.95  Because these proteins are recognized as foreign, when they are processed by the 
host cells and displayed on their surface, the immune system is alerted, which then triggers a 
range of immune responses.96  
 
 





Figure 16.  Production of recombinant viruses in cell lines (this image is used to 





Advances in Helminth Vaccines 
 
The emergence of drug resistant parasites and the limited sustainability of drug 
administration programs in endemic areas have provided great incentive for the development of 
molecular vaccines for helminth infections.97 Vaccines targeting particular proteases produced 
by helminths represent an area of which the most success in helminth vaccinology has been 
achieved. 98 
Additionally, endeavors into vaccines targeting infective helminth larvae are increasingly 
common as the adult stage of many problematic helminths are not only drug resistant but also 
less susceptible to type II immune responses.99  
 
Potential Advantages of Vaccination. 
 
 The current method of mass treatment for helminth infections is through a deworming 
campaign where the worm is either physically removed or removed by providing the infected 
with medication.100 The cost of mass deworm is little, roughly estimated at $0.25USD per child 
under WHO’s current treatment plan.101 While cost of removing helminths by medication is low, 
this style of treatment needs to be performed twice to three times yearly in areas with medium or 
high prevalence of infection.102 Additionally, deworming by medication does little to prevent 
rapid reinfection of a parasite.103 It is for this reason that a vaccine targeting helminths may be a 
more desirable form of treatment as a vaccine would likely prevent reinfection and require far 
fewer deworming campaigns as the immunity would likely stay with the inoculated for a much 
longer period of time.  
 
 
Scope of the Project 
 
The ITTI team began this project by setting the goal for the team to produce a patent landscape 
report surveying the technologies necessary to produce a vaccine targeted parasitic worms that 
infect humans.  The ITTI team then needed to limit the scope of the project in both the types of 
technologies to be surveys and the types of organizes to be surveyed.  The ITTI team set the 
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scope of the project to include the following: all types of complete vaccines, veterinary vaccines, 
methods of vaccine production and formulation, methods of producing subunits useful for 
vaccines, and general platforms related to parasitic worm vaccines. In addition, the ITTI team 
decided the scope of the project would include all species of parasitic worms that fall under the 
phyla nematoda or platyhelminthies as the members of these phyla generally have the potential 
to infect humans. 
 
The ITTI team decided that complete vaccines are relevant to the subject and thus fall within the 
scope of the project.  Although the ITTI team did not know all of the types of vaccines patents a 
landscape analysis would discover, the ITTI team subdivided the vaccine category into subunit 
vaccines and DNA vaccines.  
 
In reviewing the patents related to vaccines, the ITTI team recognized the need to address the 
issue of when the claims of a patent were directed to vaccines mainly used in animals.  Given 
that a parasitic worms can use an animal as an intermediary (also known as a vector) before 
infecting humans and that there is a need to vaccinate livestock against parasitic worms, vaccines 
directed solely to the use in animals were included as relevant documents and given a separate 
category in veterinary vaccines.104 In some cases, patent documents may have claims directed to 
a vaccine useful against all nematodes but the specification of patent would be directed towards a 
vaccine useful against parasitic worms that mainly infect livestock.105  In such cases the patent 
would be included in the relevant vaccine category and not the veterinary category. In other 
cases if the claims were directed specifically to nematodes that infect mainly animals and not 
human the patent was sorted into the veterinary vaccine category.106  
 
One of the most important decisions made was how to deal with adjuvants.  The main problem 
with adjuvants is that an adjuvant patent often claims use in vaccines for parasitic worms in a 
large Markush group, along with hundreds of other diseases.  On the other hand, an adjuvant 
could be limited to just parasitic worms.  Faced with these two issues, adjuvants were divided 
into two groups, general adjuvants, defined as an adjuvant that listed parasitic worms in a large 
Markush group, would be excluded from the report107 and related adjuvants, defined as adjuvants 
used just for parasitic worms would be considered relevant.   
                                                
104 See CA2153494C  
105 See US20100255037A1 
106 See US20030129204A1 
 
107 See US8211861B2 
 
 32 
Patent Search Methodology  
 
Guess, compute the consequences to see what that guess would imply, and 
compare directly with observation to see if it works.  If it disagrees with the 
experiment, it’s wrong.  It’s that simple.  It doesn’t matter how beautiful your 
guess is, how smart you are, or what your name is.  Looking at the universe, the 
great power of science, there’s no such thing as authority of nature.  If it doesn’t 
agree with the experiment, then it’s wrong.  







The iterative process is defined as the act of repeating a process with the aim of approaching a 
desired goal, target, or result.  Each repetition of the process is called an iteration, and the results 
of one iteration are used as the starting point for the next iteration.  In the field of patent 
searching, the iterative process is a searching methodology wherein at the end of a search cycle, 
the search is evaluated, and its shortcoming assessed.  The shortcomings are then addressed in 
the next cycle of searches in order to capture the documents.  The next search can be either wider 
in scope or could be a narrower search depending on the results gained from the previous search.   
 
In this study, keyword searching identified relevant documents, from which were extracted 
further keywords as well as classification codes.  The classification codes were used to locate 




Figure 17. Iterative development 
model.  Taken from Wikipedia. 
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Precision and Recall108 
 
The number of patent documents worldwide, including patents (issued, re-issued, and re-
examined) and applications, is over 60 million109.  Selecting relevant documents from such a 
huge dataset can be difficult, and this type of document retrieval is governed by the mathematical 
theory of Precision and Recall.  Precision is the percentage of retrieved documents that are 
relevant and is calculated as the number of retrieved relevant documents divided by the total 
number of retrieved documents.  Recall is the fraction of relevant documents retrieved and is 
calculated as the number of retrieved relevant documents divided by the total number of existing 
relevant documents.  These concepts are illustrated in Figure 7110 below.  
 
Figure 18.  Increasing precision of a search means some relevant results are excluded.  
 
Thus, any set of retrieved of documents will always include a certain fraction of irrelevant 
documents, also termed false positives.  As a search attempts to capture an ever higher fraction 
of relevant documents, the sensitivity of the search will decrease because the proportion of false 
positives will increase.  In the extreme, every relevant document can only be captured if every 
irrelevant document is also captured, as depicted in Figure 8111. 
                                                
108 See also J. Davis and M. Goadrich, The relationship between precision-recall and ROC curves, Proceedings of 
the 23rd International Conference on Machine Learning, Pittsburgh, PA, 2006. 
109 Based on data from 2007.  http://www.taeus.com/article.php?id=66.  
110 http://www.wipo.int/freepublications/en/patents/434/wipo_pub_l434_03.pdf 
111 Precision Recall Graph, Mirrored ROC Curve, www-csli.stanford.edu.  
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Figure 19.  Inverse relationship between recall and precision.   
 
Stated another way, a high recall means you haven't missed anything but you may have a lot of 
useless results to sift through (which would imply low precision).  High precision means that 
everything returned was a relevant result, but you might not have found all the relevant items 
(which would imply low recall).112 
 
             
Figure 20.  An optimal balance can be achieved which is neither 100% precise nor contains 100% recall. 
 
An optimal balance, point C in Figure 9113, must therefore be achieved between precision (degree 
of relevance of all retrieved documents) and recall (fraction of relevant documents retrieved).  In 
terms of patent searching, and in particular searching for relevant vaccine patents within the 
parasitic worm vaccine landscape, one deciding on that balance point must have experience in 
                                                
112 Wikipedia, the free encyclopedia, http://en.wikipedia.org/wiki/Precision_and_recall. 
113 http://www.ccs.neu.edu/home/jaa/CSG339.06F/Homeworks/hw.01.html. 
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patent searching in general, knowledge concerning the technology involved, and an 
understanding of the goal of the search.  The purpose of the methodology described in the 
previous report and refined in this update is to provide a framework for such a decision-making 
process.  
 
A search method example that resulted in high levels of recall and low levels of precision is 
semantic searching.  In this search method, recall was high but precision was low.  The reason 
semantic searching may have been less than effective is that the boundaries that create accuracy 
in a search, the keywords, were computer generated.  Although it is difficult to judge the 
precision levels of semantic searching based on our limited attempts, this results seem to indicate 
that the keywords generated by a computer do not result in high levels of precision.  
 
Other databases were more successful for obtaining high levels of precision.  For example, when 
the search string was controlled and the database being searched was efficient, the results that 
were obtained were an optimal balance between precision and recall.  For example, Derwent is a 
pre-screened database, where language and classifications are carefully standardized.  Therefore, 
precision is increased due to accuracy and efficiency of searching. 
  
Platform Services  
 
U.S. Patent and Trademark Office114 
ITTI utilized the USPTO database for classification searching, a patent search platform created 
by the United States Patent and Trademark Office, which provides function to search for patents 
within any of the USPTO’s classifications.  The USPTO database also allows for non-
classification searching.   
 
Thomson Innovation115 
ITTI utilized Thomson Innovation, a patent search platform that integrates the best of the suite of 
Thomson tools, Aureka, Delphion and MicroPatent.  Thomson Innovation is a single, 
integrated tool that combines intellectual property, scientific literature, business data and 
news with analytic, collaboration, and altering tools in a robust platform. 
 
TotalPatent116 
ITTI also utilized TotalPatent, a LexisNexis platform, to search patents and patent 
applications world-wide.  TotalPatent provides several additional countries that are not 
included in other platforms.  Also, TotalPatent offers useful tools such as semantic searches, 
the ability to search for subsidiary companies and corporate structure, and analytics. 
 
                                                
114 http://www.uspto.gov/.  
115 http://info.thomsoninnovation.com/.  
116 http://www.lexisnexis.com/en-us/products/total-patent.page.  
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Deduplication Process and Collapsing into Families 
 
The search results from ITTI’s secondary patent searches were combined to form a single list of 
patent documents.  The combined search results were placed into Microsoft Excel as publication 
numbers and deduplicated.  The number of duplicates was taken as an indication of the level of 
recall.  For example, a high percentage of duplicates would mean that most of the relevant results 
had been identified.  However, publications numbers with different file extensions, such as PCT 
extensions A1, A2, and A3, would be recognized as different even though the numbers 
corresponded to the same application.   
 
A further method of deduplication employed Thompson Innovation.  A publication number 
search was performed and all related INPADOC family members were returned in the result set.  
The data was saved as a work file.  The same procedure was performed with a different team 
member’s search results.  One work file could be subtracted from the other, and the size of the 
subtracted file would indicate the level of overlap and thus the level of recall being achieved.  
The work files could also be merged, and Innovation would automatically remove duplicates in 
the merged work file. 
 
Once a compiled list of all search results was deduplicated, the results were then collapsed by 
INPADOC family to reduce the initial search results into representative patent family 
documents.  ITTI gave preference to US documents because these documents were easier for the 
team to analyze and they tended to contain the most complete bibliographic information 
available.  The collapsed list was a much more manageable number of documents which the 
team could efficiently code into categories.  The team recognizes that the representative family 
member could be a divisional application and thus would not claim the full limit of the invention.  
Although this could result in an error, either towards inclusion or exclusion, time constraints 






A master of list of parasitic worm-related documents was assembled following three complete 
rounds of searching by each of the three team members.117  On the second round of searching, 
about 90% of nearly 2800 documents were repeated among the different members’ results. The 
third round of searching generated 4 new INPADOC families and 20 new patent documents. 
This increased the percent of repeated documents to nearly 99% Thus, the team was confident 
that at least 96% of the helminth-related documents had been captured.   
 
                                                
117 The keywords used in patent searching are located in Appendix L. 
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The results were compiled and a publication number search was performed using Innovation to 
expand the families.  Approximately 2847 total documents were identified, and these results 
were collapsed into almost 447 INPADOC patent families.118  Representative family members 
were then subjected to a coding process.  Publications that were irrelevant to vaccines directed 
towards helminths or were outside the scope of this project were excluded.  Documents were also 
excluded if there was too little information in the record to support a coding decision, such as 
some documents having only a title.  
 
Documents were considered relevant if they specifically claimed a member of either phylum 
platyhelminthies or phylum nematoda.  Coding was done on the claims of the representative 
family members, or, if no claims were available, coding was done using other family members.  
INPADOC family members were given preference, but DWPI family members were used 
alternatively.  Family members were selected in the following order, as available: a U.S. 
application (assumed to have the broadest claims), U.S. patent, a PCT application, and finally a 
document having claims in English, such as a document from Great Britain or Australia.  If no 
family members had claims in English, foreign language claims were translated into English 
using either a translation provided by Thomson Innovation, Lexis Total Patent, or Google 
Translate.119  If there were no family members having claims in their records, the family was 
coded using a DWPI summary of the claims, or if absolutely necessary, on the abstract alone.  In 
the final case, the coding was done very conservatively and the document was excluded unless it 
obviously related to a vaccine targeting parasitic worms.   
 
In this manner, over 98% of the results were either assigned to one of the coding categories given 
below or were excluded as outside the scope of this report.  Many documents were relevant to 
multiple categories, but each representative family was placed in only one category, that 
category being the best fit for the overall focus of the document.  For example, a document 
claiming both a complete vaccine and the components to be assembled into that vaccine was 
placed into one of the vaccine categories.  Alternatively, if the document focused on the process 
of making the vaccine, the document was coded to one of the method categories.  In general, 
there were four major categories for coding documents: vaccines, supporting technologies, 
general platforms, and excluded documents.  The first two categories were divided into 
subcategories.  The definitions and criteria for each category are given below.  The Master 





                                                
118 Results are given in approximations because new family members were continually being identified and 
publications were added to existing families.  Thus, the actual numbers changed each week with total documents 
increasing and the number of families decreasing. 
119 http://translate.google.com/.  
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Coding Categorization of Patent Documents 
 
General platforms.  
A document had to specifically claim a type of parasitic worm or parasitic worms in general to 
be considered relevant. The technology described in such documents could be useful in 
constructing a vaccine directed towards helminths, but could just as easily serve as a platform for 
vaccines against a wide range of pathogens.  These documents were considered to have a low 
level of relevance.  While these documents are captured and reported in Appendix A, they are 
not included in any of the analysis below. 
 
Vaccines. 
Vaccines were divided into two subcategories: subunit vaccines, and DNA vaccines. Subunit 
vaccines contain individual helminth antigens or a mixture of a limited number of antigens. The 
antigens could either be a portion of a helminth120, a purified surface antigen of a helminth121 or a 
chemical a helminth excretes.122  The subunits could be also be expressed by viruses, bacteria, or 
other organisms that act as a carrier for a helminth antigen. 
 
 DNA vaccines are nucleic acid constructs which, when injected into an animal, cause 
expression of an helminth antigen by host cells that take up the nucleic acid constructs These 
nucleic acid constructs could be either linear pieces of DNA or RNA, which are short-lived in 
the host, or DNA plasmids, which can persist for a period of time.123 
 
 To be considered a vaccine-related publication, the representative document must have 
claimed compositions of matter having all aspects of a true vaccine: antigen(s), adjuvant (if 
necessary), carriers/diluents, and a means or route of delivery.  If the claims do not meet these 
aspects, or were solely method claims, the family was placed in one of the supporting technology 
categories.  Merely terming a composition was not sufficient; the claims must have had enough 
detail to describe an actual vaccine.  Some allowance was made for foreign language documents 
in that a broader range of terminology was accepted as a description of a vaccine. 
 
Supporting Technologies. 
Some documents claimed parasitic worms in the independent claims yet did not sufficiently 
claim a vaccine composition for use in humans. These documents describe the antigenic 
components of a vaccine, but lack detail of carriers, adjuvants, and route of administration.    
Thus, these documents were coded as one of the supporting technologies which are important for 
the construction or manufacture of vaccines.  Included in the supporting technologies 
                                                
120 See US4756908A 
121  Id. 
122 See AU2003294191B2 
123 See US5021342A; see also, CN100528240C 
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subcategories is novel subunit constructs useful in vaccines. As such, these two subcategories 
were focused on compositions of matter. 
 
Two other subcategories of the supporting technologies were focused more on methods utilized 
in vaccine manufacture.  The first such subcategory contains documents describing methods of 
making vaccines. The other subcategory contained documents describing methods of producing 
subunits useful for vaccines.  These method including nucleic acid constructs which could be 
used to produce recombinant viruses,124 or cell lines which could be used to produce subunits125 
While the former subcategory was mostly for method patent documents, the latter subcategory 
contained a mixture of method and composition of matter claims. 
 
A final subcategory under the heading of supporting technologies was for veterinary vaccines.  
While the documents in this subcategory described complete vaccines, those vaccines were not 
for use in humans, although it is possible some may have been able to be adapted for human use.  
These vaccines were targeted towards pigs, horses, dogs, and other domesticated animals.  Such 
vaccines may be useful not only veterinary purposes but also to prevent transmission of parasitic 
worms to humans. Veterinary vaccines were included in the relevant dataset for analysis as the 
line between purely veterinary vaccine, veterinary vaccines with human applications, and 
vaccines with veterinary applications was generally too close to make an absolute call on 
whether to include or exclude veterinary related documents.  
 
The heading of supporting technologies thus contains a broad spectrum of patent documents 
covering a variety of different technologies.  However, all of these documents are relevant to the 
production of helminth vaccines and the prophylactic treatment of human populations.  The 
entire list of these documents is presented in Appendix A.  
 
Note on the order of placement  
As mentioned above, relevant documents may fit in multiple categories, but these documents 
were placed in the category which was the most relevant to the overall focus of the document.  
The order of placement was: 
1. Subunit vaccines 
2. DNA vaccines 
3. Subunits useful for vaccines 
4. Methods of making vaccines 
5. Methods of producing subunits 
6. Veterinary vaccines 
                                                
124 See CN102277373A  
125 See IN200705429P4 
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Documents were placed in the highest category in which the claims from that document fit.  
However, if no claims were available in the record of that document or any of its family 
members, the document were conservatively coded, mostly in the lower categories.  If the 
available record mentioned multiple pathogens, the document without claims was often placed in 
the platform category. 
 
Excluded irrelevant documents 
Approximately half of the documents were excluded as irrelevant or as having insufficient 
information to allow coding.  The full list of these documents can be found on the Master Coding 
Sheet in Appendix A, but it is useful to detail the reasons for exclusions here, to clarify the scope 
of the project. 
 
1. Therapeutic interventions, such as small molecule medicines. 
2. Means of detecting the presence of a parasitic worm. 
3. Diagnostic methods. 
4. Passive immunization. 
5. Antibodies directed against helminths.  These could be used in any of the above 
categories.  A few patent document mentioned using anti-helminth antibodies to stimulate 
anti-idiotype responses, but few of those documents disclosed an anti-idiotype 
monoclonal antibody that could be used to immunize humans. 
6. Adjuvants, when a parasitic worm is not specifically claimed. 
7. Use of helminths in autoimmune therapy. 
8. Use of helminths for agricultural purposes 
9. Delivery systems for vaccines. 
10. Immunization schedules, when a particular vaccine formulation is not disclosed. 
11. Documents actually related to Plasmodium, a protozoa responsible for malaria.  Searches 
for the helminths often returned this pathogen as well. 
12. Documents which were not related to helminths. 
 
 
Distribution of coding categories 
The relative distribution of the results into the various categories is given in Table I.  Almost half 
of the search results were considered relevant as either a vaccine document or a document 
describing one of the supporting technologies.  Analytics was performed on these patent 
documents.  The remainder of the results are reported in the appendix but were not included in 
the analysis. 
 
Table I. Distribution of results (210 families) into coding categories. 
Cestode 12.9% 
Vaccines 6.7% 
           Subunit vaccines 6.2% 
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           DNA vaccines 0.5% 
Supporting Technologies 6.2% 
          Novel subunits useful in vaccines 4% 
          Method of making vaccines 1.5% 
          Veterinary vaccines 0.7% 
Nematodes 30.5% 
Vaccines 12.9% 
           Subunit vaccines 12% 
           DNA vaccines .9% 
Supporting Technologies 17.6% 
          Novel subunits useful in vaccines 5.2% 
          Method of making vaccines 1.9% 
          Veterinary vaccines 10.5% 
Trematodes 49% 
Vaccines 23.3% 
           Subunit vaccines 16.2% 
           DNA vaccines 7.1% 
Supporting Technologies 26.2 
          Novel subunits useful in vaccines 21.4 
          Method of making vaccines 4% 
          Method of producing subunits .5% 
          Veterinary vaccines .5% 
Non-Distinguished 8.1% 
Vaccines 3.33% 
           Subunit vaccines  3.33% 
           DNA vaccines 0.0% 
Supporting Technologies 4.8% 
          Novel subunits useful in vaccines .95% 
          Method of making vaccines 2.4% 
          Veterinary vaccines .95% 
Platform technologies 2.0% 
Excluded as irrelevant 50.1% 
 
Relevant Helminth Vaccine and Vaccine Technology Documents 
 
Searching was done for helminth-related patent documents which were then categorized based 
on their relationship to vaccines for parasitic worms.  Not all documents were specific as to 
whether the technology could be used towards helminths that infect predominately human; 
helminths that infect predominately animals; or both.  The team decided to err on the side of 
inclusion, so that a document was considered relevant if it mentioned a vaccine that targeted 
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helminths generally, a helminths that can infect humans. Documents representing each family are 
presenting in Table II.  Full information on those documents can be found in Appendices B and 
C. 
 




Title - DWPI Assignee/Applicant 
AU2010241253B2 Constructing peptides based on three-
dimensional structure of homologs, 
useful as vaccines for protecting 
against helminth infections and for 
diagnosis 
FUNDACAO OSWALDO CRUZ 
US8211438B2 Vaccine composition useful for 
vaccinating a patient against 
hookworm infection, comprises 
hookworm antigens Na-APR-1 and 
Na-GST 
The George Washington 
University,Washington,DC,US 
BRPI9808251B1 Protective protein derived from 
parasite protease, e.g. Fasciola 
hepatica may be detected using ex 
vivo animal model, useful for, e.g. 
vaccinating mammals against 
parasite 
 
ES2376874T3 Novel Schistosoma mansoni 
recombinant protein of specific 
molecular weight, useful as 
protecting antigen against 
Schistosoma and Fasciola infection 
affecting humans and animals 
FUNDACAO OSWALDO CRUZ 
US7303752B2 Composition useful for vaccinating 
or eliciting immune response against 
hookworm in mammal, comprises 
copy of recombinant or synthetic 
antigen or their fragments derived 
from hookworm, and carrier 
The George Washington 
University,Washington,DC,US 
US20070079388A1 Composition for producing immune 
response, comprises human 
hookworm, in carrier, and human 
hookworm is produced by 
administering non-adapted human 
hookworm to non-human primate, 
obtaining fecal material, isolating 
human hookworm 
The Secretary of State for Defence 
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US7144878B2 Preventing and treating roundworm 
infestations in animals, comprises 
orally administering parasiticidal 
formulation comprising non-aqueous 
liquid, thickening agent and different 
agents effective against nematodes to 
animals 
IVX Animal Health Inc.,St. 
Joseph,MO,US 
CA2153494C New parasitic helminth proteins, 
pref. from Dirofilaria immitis used to 
protect animals from helminth 
infection, pref. heartworm 
COLORADO STATE UNIVERSITY 
RESEARCH FOUNDATION,FORT 
COLINS,CO,US | HESKA 
CORPORATION,FORT 
COLLINS,CO,US 
US6790630B1 New Dirofilaria immitis parasite 
protein exhibiting antigenic cross-
reactivity with human Onchocerca 
volvulus filarial parasite protein and 
immune-reactivity with sera having 
heartworm infection, for diagnosis of 
heartworm infection 
New England Biolabs Inc.,Beverly,MA 
US6756043B2 Composition containing polypeptides 
from adult Taenia solium, useful for 
detecting taeniasis, particularly 
differentiation between infection by 
adults and larvae 
The United States of America as 
represented by the Department of Health 
and Human Services Centers for Disease 
Control and Prevention,Washington,DC 
CA2403985C Inducing angiogenesis in a tissue 
using the Ov-ASP protein isolated 
from the nematode Onchocera 
volvulus is useful to treat circulatory 
or vascular disease such as ischemia 
NEW YORK BLOOD CENTER 
INC.,NEW YORK,NY,US | CASE 
WESTERN RESERVE 
UNIVERSITY,CLEVELAND,OH,US | 
THE UAB RESEARCH 
FOUNDATION,BIRMINGHAM,AL,US 
DE69737691T2 Vaccine for controlling infection by 
helminth parasites containing new 
peroxiredoxin or beta-tubulin, 
particularly used to combat liver 
fluke 
Dalton John Pius Blackrock Dublin IE 
US6673345B2 Novel isolated protein useful for 
identify a compound capable of 
inhibiting astacin metalloproteinase 
activity of a parasite 
Heska Corporation,Fort Collins,CO 
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US20050208063A1 Thiol proteases with Cathepsin L-
type activity useful in vaccine 
formulations against helminth 
parasites 
John P. Dalton,Dublin,IE 
US6489448B1 Nucleic acid encoding thiol-specific 
antioxidant protein of helminth 
larvae useful for treatment or 
prevention of helminth infection, 
specifically heartworm 
Heska Corporation,Ft. Collins,CO 
US6455039B2 Isolated parasitic helminth 
macrophage migratory inhibitory 
factor and related nucleic acid, useful 
for protecting animals from 
heartworm or onchocerciasis. 
Heska Corporation,Ft. Collins,CO 
US6414115B1 New isolated parasitic nematode 
transglutaminase genes used to 
develop products for the detection, 
prevention and treatment of 
infections by parasitic nematodes 
Heska Corporation,Fort Collins,CO | 
Board of Regents The University of 
Texas System,Austin,TX 
US6413521B1 A helminth parasite antigen with 
aminopeptidase like activity for use 
in vacuums to stimulate an immune 
response against helminth parasites 
pref. gastric nematodes of the gastro-
intestinal tracts of mammals 
The Barbraham Institute,Cambridge,GB 
US6392017B1 A new parasitic helminth Antigen-2 
protein, designated DiAg2, from 
Dirofilaria immitis reacts with sera 
from immune dogs and is useful to 
prevent and treat parasitic helminth 
infection, particularly heartworm in 
dogs 
Heska Corporation,Fort Collins,CO 
US6365569B1 New ankyrin proteins encoded by 
nucleic acids which hybridize to 
nucleic acids from Dirofilaria and 
Brugia are useful to immunize 
against platyhelminth parasites which 
cause disease such as heartworm, 
elephantitis and hydrocele 
Heska Corporation,Fort Collins,CO 
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US6352836B1 New isolated thioredoxin peroxidase 
type-2 nucleic acid obtained from a 
Dirofilaria and Brugia, used to 
develop products for protection 
against parasite helminth disease 
such as heartworm disease 
Heska Corporation and Colorado State 
University Research Foundation,Fort 
Collins,CO 
BR199815440A Homogeneous population of parasite 
cells for long term in vitro culture 
particularly derived from nematodes, 
suitable for use in vaccines, also 
related antibodies and anti-idiotypic 
antibodies for diagnosis of infestation 
and treatment 
UNIV MISSISSIPPI 
US5948644A Excretory-secretory antigens from 
parasitic nematode(s) confer 
immunity to responsive hosts to 
parasitic nematode stages 
Biotechnology Australia Pty 
Ltd.,Roseville,AU | Commonwealth 
Scientific & Industrial Research 
Org.,Campbell,AU 
US5942413A Vaccines comprise antigens derived 
from parasitic nematodes useful for 
passive immunisation against 
roundworm, whipworm, filarial 
worm, threadworm and hookworm. 
Biotech Australia PTY 
Limited,Roseville,AU | Commonwealth 
Scientific and Industrial Research 
Organization,Campbell,AU 
DK703789T3  ANDREWS STUART JOHN | 
DALTON JOHN PIUS 
US5871738A Antigens derived from parasitic 
nematodes used in vaccines against 
hookworm, roundworm, whipworm, 
filarialworm, or threadworm 
Biotech Australia Pty. 
Limited,Roseville,AU | Commonwealth 
Scientific and Industrial Research 
Organization,Campbell,AU 
CA1340301C Protein derived from parasitic 
nematode species used to provide 
protective immunity against 
nematode parasites of man and 
domestic animals 
COMMONWEALTH SCIENTIFIC 




EP836481A4  HESKA CORP 
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US20030091591A1 Use of packaging defective alpha-
virus expression vectors for prodn. of 
protective cpds. for protecting 
animals from disease, partic. 
toxoplasmosis 
HESKA CORPORATION 
US5753236A New epitope contg. fragments of 
Schistosoma mansoni 28 kD protein 
prepd. by digestion with V8 protease, 
useful as vaccine components 
Institut Pasteur de Lille,Lille,FR | Institut 
Pasteur,Paris Cedex,FR 
JP03103592B2 Protein complex parasitic nematode 
useful as an immunogen and 
anthelmintic agent in vaccine 
MUNN E A 
DE4419264B4 Sm14 from Schistosoma mansoni 
binds fatty acids and confers up to 
100 percent helminth infection 
protection; useful in vaccinations 
against helminth diseases. 
Fundação Oswaldo Cruz (Fiocruz) Rio 
de Janeiro BR 
CA2215529C Vaccine which protects animal from 
Trichinella infection comprises beta-
tyvelose-contg. compsn. or 
mimetope, which is beta-tyvelose or 
beta-tyvelose joined through 
glycosidic linkage to 
mono:saccharide to form 
oligosaccharide, and excipient 
COLORADO STATE UNIVERSITY 
RESEARCH FOUNDATION,FORT 
COLINS,CO,US 
US5618542A Antigenic polypeptide(s) of Taenia 
ovis used in vaccines to protect 
ruminants against infection by 
cestode parasites and to develop 
identifying probes 
Coopers Animal Health NZ 
Limited,Upper Hutt,NZ | University of 
Melbourne,Victoria,AU | Ministry of 
Agriculture & Fisheries,Wellington,NZ 
DK173779B1 New protein contg. epitopes of P28 
Schistomonas antigen corresp. DNA 
sequences and transformed cells and 
viruses, useful in vaccines and 
diagnosis 
TRANSGENE SA 
US5541078A New immunogenic peptide sequence 
from Echinococcus granulosus for in 
vitro diagnosis of hydatidosis by 
ELISA and radioimmunological 
methods, also as vaccine against 
Institut Pasteur de Lille,Lille Cedex,FR | 
Institut National de la Sante et de la 
Recherche Medicale (Inserm),Paris 




US5492695A Vaccine for susceptible hosts against 
non-adapted parasites e.g. dirofilaria 
immitis esp. used to protect cats 
against heart-worm 
Colorado State University Research 
Foundation,Fort Collins,CO,US 
US5422263A DNA encoding sequence 
homologous to trichinella spiralis 
sequence of 53 kilodalton excretory-
secretory antigen used in diagnosis 
and as vaccine for trichinellosis 
The United States of America as 
represented by the Secretary of 
Agriculture,Washington,DC,US 
JP02759652B2 Membrane associated proteins from 
nematodes used in the prodn. of 
vaccines against haemonchosis, 
ostertagiasis and other nematode 
infections 
BABURAHAMU INST 
US5219566A New cDNA encoding polypeptide of 
Schistosoma mansoni includes 
protein epitope(s) present on 
Schistosomula surface, used in 
vaccines against bilharziasis 
The Johns Hopkins 
University,Baltimore,MD,US 
US5021560A Glyco:protein cpds. from mollusc 
haemo:cyanine and glycan epitope(s) 
with same antigenicity as shistosoma 
mansoni surface antigen, useful for 
making anti-bilharzia vaccines and 
protective sera 
Institut Pasteur,Paris,FR | Institut Pasteur 
de Lille,Lille,FR | Institut National de la 
Sante et de la Recherche Medicale 
(INSERM),Paris,FR 
US5021342A DNA encoding onchocerca/volvulos 
volvulos antigen used to express 
recombinant antigen for vaccine 
against onchocerciasis or river 
blindness 
University Hospitals of 
Cleveland,Cleveland,OH,US 
USN7366844N DNA encoding sequence 
homologous to trichinella spiralis 
sequence of 53 kilodalton excretory-
secretory antigen used in diagnosis 
and as vaccine for trichinellosis 
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US4795633A Vaccine for swine Trichinosis 
comprising inert new:born larvae of 
Trichinella spiralis emulsified with 
an adjuvant 
The United States of America as 
represented by the Secretary of 
Agriculture,Washington,DC,US 
IE59292B1  BRITISH TECH GROUP 
USN7068499N Vaccine for swine Trichinosis 
comprising inert new:born larvae of 
Trichinella spiralis emulsified with 
an adjuvant 
 
US4656033A Vaccine against Schistosoma 
mansoni contg. soluble antigen from 
larvae or adults, administered with 
BCG adjuvant 
The United States of America as 
represented by the Department of Health 
and Human Services,Washington,DC,US 
US4396600B1 Antigenic prepn. obtd. by saline extn. 
of schistosome worms useful in 
vaccines against schistosome 
infections 
 
US4314992A Fascioliasis vaccine prodn. by 
gamma irradiation of 
meta:cercaria(e) obtd. by infecting 
Lymnaea natalensis snails with 
Fasciola gigantica miracidia 
BITAKARAMIRE PETER K 
US3676547A Ascaris suum vaccine for pig 
immunization obtd from second and 
third stage larvae 
Eli Lilly and 
Company,Indianapolis,IN,US 
US3395218A Anti-nematodal vaccines ALLEN & HANBURYS LTD 
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US20130064853A1 New antigens from the fourth stage 
larvae of non-blood feeding parasitic 
nematodes, useful for raising an 
immune response and for treating, 
preventing or reducing symptoms of 
diseases such as Bovine ostertagiasis 
Smith William David,Penicuik,GB | 
Newlands George Fredrick 
James,Penicuik,GB | Smith 
Stuart,Penicuik,GB | Halliday 
Aileen,Penicuik,GB 
EP2531210A1 New isolated antigen useful in e.g. 
vaccine for protecting a mammal 
against Strongyloides stercoralis 
infection, comprising Strongyloides 
stercoralis immunoreactive antigen 
protein 
The United States Of America As 
Represented By The Office of 
Technology Transfer National Institutes 
Of Health,Bethesda, Maryland 20892-
7660,US,101263691 | Thomas Jefferson 
University,Philadelphia, PA 
19107,US,101093759 
US20120128721A1 Large scale production of a full 
length Schistosomal paramyosin 
coiled coil dimmer composition 
comprises contacting a composition 
comprising recombinant paramyosin 
with a strand separation agent 
 
JP2012519496A Recombinant Bacillus Calmette-
Guerin auxotrophic Pasteur strain 
used for controlling human infections 
caused by parasites e.g Schistosoma 
mansoni, and for controlling tumors, 
is supplemented for amino acid 
leucine 
 
US20110200640A1 Multivalent anti-helminthic vaccine 
comprises recombinant hookworm 
antigens and recombinant 
schistosome antigens, useful for 
vaccinating an individual against 
hookworm infection and 
schistosomiasis 
 
US20110158998A1 Novel isolated protein comprising 
immunogenic, extracellular fragment 
of schistosome tegument protein 
tetraspanin-1 TSP-1, TSP-2 or 7TM, 
useful for preparing 
immunotherapeutic composition for 
immunizing against schistosomiasis 
THE COUNCIL OF THE 
QUEENSLAND INSTITUTE OF 
MEDICAL 
RESEARCH,Queensland,AU 
EP2264057A4  UNIV GRANADA 
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EP2485725A2 Composition, useful e.g. for the 
prevention or control of parasitic 
infection (Helminthiasis and Fasciola 
species) in warm-blooded animal e.g. 
sheep, comprises oil adjuvant, 
macrocyclic lactone e.g. milbemycin, 
and immunogenic polypeptide 
PAH W LLC,New York NY 10017-
5755,US,101347569 
CN102596226A Vaccine composition useful for 
preventing schistosomiasis comprises 
a full length cDNA of the large 
subunit of Schistosoma mansoni 
calpain cloned into a vector 
UNIV TEXAS TECH SYSTEM,US 
US20100255037A1 New isolated Haemonchus contortus 
polynucleotide and polypeptide, 
useful for manufacturing 
immunogenic composition for 
preventing or treating H. contortus 
infection in an animal, and for 
identifying analogous proteins from 
other helminths 
 
US20030176382A1 New vaccine composition for the 
treatment of hookworm infection 
comprises aspartyl proteinase from 
Necator americanus 
 
US20030129204A1 Protective helminth parasite antigen 
used in vaccine directed against 
parasitic nematodes of mammalian 
gastro-intestinal tract e.g. 
Haemonchus contortus 
Moredun Scientific Limited,GB 
EP992582A3  University of Wales Bangor,Bangor, 
Gwynedd LL57 2DG,GB,02522642 
AU2003294191B2 New polypeptide produced in a 
genetically modified microorganism 
containing the amino-acid sequence 
of the liver fluke cysteine protease 
fused to the sequence of hepatitis B 
virus core protein, for use as a 
vaccine against liver fluke 




AU2003295293B2 New chimeric protein containing 
cysteine protease of the liver fluke 
fused to hepatitis B core protein or 
ubiquitin, useful in treating liver 
fluke infection and in inducing 
immunicity 
INST OF BIOORG CHEMISTRY | 
INST OF PARASITOLOGY POLISH 
AC | INST OF BIOTECHNOLOGY 
ANTIBIOT 
RU2145876C1 Use of anti-helminth vaccines to 
control disease associated with loss 
of natural immunity esp. for control 
of periparturient rise of Haemonchus 
in sheep and of type II ostertagiasis 
MALLINKRODT VETERINARI INK 
EP2328610A2 Immunogenic formulation useful for 
protecting and/or treating an animal 
against a parasitic nematode, and for 
vaccinating a susceptible animal 
against infection from the parasitic 
nematode 
Moredun Research Institute,Bush Loan, 
Penicuik EH16 0PZ,GB,101167975 
CN101563103A Identifying anthelmintic agents 
comprises contacting an agent with a 
helminth protein having dipeptidyl 
peptidase IV activity and resulting in 
an increase in blood clotting time 
MOREDUN RES INST,GB 
JP2000500474A Isolated nematode antigens useful for 
diagnosis, prevention and therapy of 
nematode infections prepared by 
culturing L4-stage nematode larvae 
in vitro in which antigens 
immunoreact with protective 
antiserum raised against L3 to L4 
stage 
 
EP707597A4  MALLINCKRODT VETERINARY 
LTD | UNIV MELBOURNE | 
PASTORAL AGRIC RES INST NZ 
LTD 
EP694043A4  MALLINCKRODT VETERINARY 
LTD | UNIV MELBOURNE | 
PASTORAL AGRIC RES INST NZ 
LTD 
 52 
EP772679A1 New Schistosoma, partic. S. 
haematobium proteins for use as 
pharmaceuticals, partic. as vaccines, 
blood processing agents and as 
anticoagulants 
IMPERIAL COLLEGE OF SCIENCE 
TECHNOLOGY & MEDICINE,London 
SW7 2BB,GB,00633556 
BR199404004A Isolated polypeptide from Fasciola 
species useful as vaccines against e.g. 
spread of infection of liver fluke 
DARATECH PTY LTD 
JP8503935A Monoclonal antibodies specific for 
nematode beta-tubulin and vaccines 
contg. a nematode antigen used to 
immunise against parasitic infection, 
pref. filariasis. 
 
EP554064A1 Vaccine against schistosomiasis 
comprising recombinant Schistosoma 
mansoni integral membrane protein 
or its derivs. 
YEDA RESEARCH AND 
DEVELOPMENT CO. LTD.,Rehovot 
76100,IL,00268945 
AU638728B2 Vaccine composition for gastro-
intestinal nematode infections 
comprises antigenic component of 
e.g. Ostertagia circumcinta extract 
DARATECH PTY LTD 
EP434909A3 Protein from Haemonchus contortus 
and other nematodes used as 
therapeutic and prophylactic agent to 
protect plants, animals or humans 
from parasitic nematode infection 
SYNERGEN INC 
AU634754B2 Vaccine against liver fluke infection 
in ruminants. esp. sheep comprises 
glutathione-S-transferase extracted 
from adult fasciola hepatica worms 
DARATECH PTY LTD 
AU198826483A Monoclonal antibody binds to 68 KD 
antigen of schistosoma mansoni to 
give immunity 
UNIV CLEVELAND HOSPITALS 
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PT84788B  INST NAT SANTE RECH MED | 
PASTEUR INSTITUT 
NZ214215A  BIOTECH AUSTRALIA PTY LTD 
AU198426739A Helminth parasitosis e.g bilharziasis 
vaccine-medicament is derived from 
e.g. ecdysterone, pref. coupled with a 
macromolecule esp. protein(s) e.g. 
serum albumin 
IMMUNOTECH SA 
KR2012110430A New protein useful for diagnosing 
and treating liver fluke infection, 





WO2012145355A1 Composition useful for e.g. 
producing immune response in 
subject and immunizing subject 
against Schistosoma infection, 
comprises slurry matrix, and antigens 
UNIVERSITY OF GEORGIA 
RESEARCH FOUNDATION INC.,US | 
HARN Donald A.,US | QUEIROZ 
Rafaella,US | MCEWEN Lisa,US 
WO2012104837A1 Composition useful as antinematodal 
composition for treating nematode 
e.g. Trichuris muris infection in 
subject e.g. human and animal, 
comprises non-insect cell or viral 
particle expressing exogenous 
nematode fusogenic protein 
TECHNION RESEARCH AND 
DEVELOPMENT FOUNDATION 
LTD.,IL | UNIVERSITY OF VIRGINIA 
PATENT FOUNDATION,US | 
PODBILEWICZ Benjamin,IL | 
AVINOAM Ori,IL | WHITE Judith 
M.,US 
WO2012067866A3 New multivalent vaccine comprising 
isolated antigens from filarial 
nematodes, useful for preventing or 
controlling filariasis in humans and 
animals 
THE BOARD OF TRUSTEES OF THE 
UNIVERSITY OF ILLINOIS,US | 
KALYANASUNDARAM 
Ramaswamy,US 
BRPI1005855A2  FUNDACAO OSWALDO CRUZ | 
ALVOS CONSULTORIA 
DESENVOLVIMENTO E COM 
IZACAO DE PRODUTOS 
BIOTECNOLOGICOS S A 
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AR76555A1  VERENIGING VOOR CHRISTELIJK 
HOGER ONDERWIJS | STICHTING 
TECH WETENSCHAPP 
FR2898276B1  CENTRE NAT RECH SCIENT | UNIV 
CLAUDE BERNARD LYON | ECOLE 
NATIONALE VETERINAIRE | 
CAMBRIDGE ENTERPRISEA | UNIV 
DE LA REPUBLICA | ISNTITUT 
AGRONOMIQUE ET VETERI 
BR200413944A New isolated nucleic acid molecule 
encoding a Schistosoma mansoni 
protein, useful for as a vaccine or for 
preventing, diagnosing, or treating 
Schistosoma mansoni infection 
FUNDACAO DE AMPARO A 
PESQUISA 
CO5210982A1  NOVARTIS AG | AGRICULTURE 
VICTORIA SERV PTY 
AU199720786A Vaccine for schistosomiasis 
comprising a non-integrating DNA 
sequence encoding Schistosoma 
mansoni glutathione S-transferase 
UNIV SOUTH ALABAMA 
AU199655380A New vaccines for filarial parasite 
infection(s) comprising C-terminal 
beta-tubulin amino acid sequence 
from a parasite 
UPJOHN CO | UNIV MCGILL 
AU199535747A Vaccines against helminth parasites 
contain haemo-protein derived from 
e.g. flukes such as Fasciola hepatica 
for treating cattle 
MALLINCKRODT VETERINARY 
INC 
ZA199408729A Protective helminth parasite antigen 
is used in the stimulation of an 
immune response against helminth 
parasites in mammals 
BIOTECH & BIOLOG SCIEN RES 
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FR2656626B1  PASTEUR INSTITUT 
WO1990002563A1 Vaccine against Schistosoma 
mansoni comprising antigens present 
in surface membrane of adult worm 
MEDICAL RESEARCH COUNCIL | 
SIMPSON Andrew John George | 
SMITHERS Sidney Ronald 
AU198778719A New recombinant DNA coding for 
helminth parasite antigen and derived 
polypeptide(s), useful for making 
vaccines and diagnostic antibodies 
UNIV AUSTRALIAN 
DE2936061C2 Vaccine for birds consists of avian 
blood contg. immune factors against 
viruses, bacteria, protozoa, 
nematodes, trematodes and/or fungi 
Schmidt Werner Dr.,DE | Wessjohann 
Berthold,DE 
FR2573983B1  LEW KENNETH 
GB1580539A Orally administrable antiparasitic 
vaccine for immuno-prophylaxis of 
trichostrongylosis, strongylosis etc. 
opt. administered with adjuvants such 
as tetramisole and levamisole 
INST NAT SANTE RECH MED 
DE1160139A1 Non-living vaccines contng. antigens 
stimulating production in the host of 
antibodies and which give protection 
when injected against diseases 
caused by nematod 
 
CH370526A  UNIV GLASGOW 
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FR2689906B1  INST NAT SANTE RECH MED | 
PASTEUR INSTITUT 
FR2688008B1  INST NAT SANTE RECH MED | 
PASTEUR INSTITUT 
JP02672712B2   
JP1457233C   
JP05055522B2 Novel EMY162 polypeptide 
specifically inducing antibodies 
specific to Echinococcus 
multilocularis, useful as vaccine 
against Echinococcus multilocularis 
infectious disease, or as marker for 
diagnosing Echinococcus infection 
UNIV HOKKAIDO,JP | HOKKAIDO 
PREFECTURE,JP 
JP03692396B2 New DNA encoding a 14 kDa 
antigen of Ascaris suum infective 
larvae, for producing the antigen 
protein which is used in a systemic 
and mucosa-inductive type vaccine 
DOKURITSU GYOSEI HOJIN 
NOGYO SEIBUTSU SH 
JP03613577B2 Novel DNA having biological 
activity of 16kDa antigen protein of 
the pig roundworm, useful as vaccine 
for pig roundworm infection 
DOKURITSU GYOSEI HOJIN 
NOGYO SEIBUTSU SH 
CN102558306A New epitope comprising specified 
amino acid sequence, useful for 
preventing and/or treating nematode 
disease, such as Trichinella disease 
or infection 
Capital University of Medical 
Sciences,CN 
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CN102392031A New Schistosoma japonicum gene 
which is thioredoxin glutathione 
reductase gene having specific amino 
acid sequence, used in vaccine for 
preventing or treating bilharziasis 
Shanghai Veterinary Research Institute 
CAAS,CN 
CN102337265A New Taenia solium microsomal 
RNA (microRNA), useful for 
preparing Taenia solium vaccine or 
composition for restraining growth 
and development of Taenia solium 
Institute for Parasitic Disease Chinese 
Center for Disease Control and 
Preventi,CN 
CN102329798A New Taenia saginata microRNA, 
useful for preparing T. saginata 
vaccine or composition for inhibiting 
growth and development of T. 
saginata 
Institute for Parasitic Disease Chinese 
Center for Disease Control and 
Preventi,CN 
CN102329385A New Schistosoma japonicum anti-
apoptosis protein, useful for 
preparing medicine for preventing 
and treating Japanese schistosomiasis 
Shanghai Veterinary Research Institute 
CAAS,CN 
CN102277373A Salmonella expression vector 
secreting attenuated Schistosoma 
japonicum vaccine useful for 
preparing Schistosoma japonicum 
vaccine, comprises bacterial 
promoter regulating Salmonella 
secretion effector protein and 
secretion signal 
NANJING UNIVERSITY,CN 
CN102168100A New Echinococcus granulosus 
glutathione transferase gene, useful 
for preparing a vaccine for cystic 
echinococcosis 
Institute for Parasitic Disease Chinese 
Center for Disease Control and 
Preventi,CN 
CN102168089A New calcium reticulated protein gene 
of Echinococcus granulosus, useful 
for preparing vaccine for 
immunization against Echinococcus 
granulosus disease, and for preparing 
diagnostic reagent for diagnosing 
cystic echinococcosis 
Institute for Parasitic Disease Chinese 
Center for Disease Control and 
Preventi,CN 
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CN102167735A New recombinant antigen protein of 
Schistosoma japonicum SjTollip 
useful in preparing vaccine for 
preventing and treating Schistosoma 
japonicum 
Huazhong Normal University,CN | 
Institute for Parasitic Disease Chinese 
Center for Disease Control and 
Preventi,CN 
CN102040658B New Schistosoma japonicum 
polypeptide with immunogenicity is 
useful for preparing vaccine for 
preventing schistosomiasis or drug 
for treating schistosomiasis, and for 
preparing product for diagnosing the 
schistosomiasis 
Shanghai Veterinary Research Institute 
CAAS,CN 
CN102079783A New Schistosoma japonicum protein, 
useful for preparing vaccine for 
preventing or treating schistosomiasis 
and preparing a product for 
diagnosing schistosomiasis 
Shanghai Veterinary Research Institute 
CAAS,CN 
CN102070710A New Clonorchis sinensis specificity 
GRA2a antigenic protein, useful for 
preparing a medicament for treating, 
diagnosing or preventing infection 
caused by C. sinensis 
Institute for Parasitic Disease Chinese 
Center for Disease Control and 
Preventi,CN 
CN102010863A New microRNA of Ascaris suum 
having difference in sex expression 
useful for preparing Ascaris suum 
vaccine or Ascaris lumbricoides 
vaccine 
South China Agricultural University,CN 
CN101985468A New SJ16 recombinant protein, 
useful for preparing a bilharziasis 
diagnostic reagent, a bilharziasis 
vaccine and a medicine for treating 
bilharziasis, and as an 
immunosuppressive agent 
SUN YAT-SEN UNIVERSITY,CN 
CN101948836A New Schistosoma japonicum zinc 
finger protein coding gene useful for 
preparing genetically engineered 
vaccine for preventing Schistosoma 
japonicum infection 
Shanghai Veterinary Research Institute 
CAAS,CN 
CN101935659A New microRNA isolated from female 
adult Ascaris suum useful for 
preparing ascarid vaccine, preferably 
Ascaris suum vaccine or human 
ascarid vaccine 
South China Agricultural University,CN 
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CN101935658A New microRNA specifically 
expressed in Ascaris suum male 
adult, used for preparing ascarid 
vaccine for affecting human ascarid 
physiological function or sexual 
development and differential function 
for preventing ascariasis 
South China Agricultural University,CN 
CN101921787A New adenosine deaminase gene 
isolated from Schistosoma 
japonicum, useful for useful for 
preparing medicine and schistosome-
resisting antibody, screening drugs, 
and in serology diagnosis process and 
gene therapy 
Shanghai Human Gene Team Research 
Centre,CN 
CN101921783A New Schistosoma japonicum L-lactic 
dehydrogenase gene useful in 
serodiagnosis, screening medicines 
and in preparing Schistosoma 
antibody 
Shanghai Human Gene Team Research 
Centre,CN 
CN101921768A New 14-3-3 protein gene useful for 
preparing medicine and schistosome-
resisting antibody, screening drugs, 
and in serology diagnosis process and 
gene therapy 
Shanghai Human Gene Team Research 
Centre,CN 
CN101921767A New Schistosoma japonicum MF3 
gene useful for preparing 
schistosome vaccine and 
schistosome-resisting antibody, 
screening drugs, and in serology 
diagnosis process and gene therapy 
process 
Shanghai Human Gene Team Research 
Centre,CN 
CN101838639A New Schistosoma japonicum 
proteasome alpha 5 subunit (SjPSM 
A5) recombinant antigen, useful for 
preparing preventative vaccines for 
schistosomiasis japonica 
Shanghai Veterinary Research Institute 
CAAS,CN 
CN101748139A New Schistosoma japonicum enolase 
gene, useful for gene therapy, and for 
preparing Schistosoma vaccine, 
selecting medicines, preparing 
Schistosoma antibody, and 
serological diagnosis 
Shanghai Human Gene Team Research 
Centre,Shanghai 201203,CN 
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CN101748138A New Schistosoma japonicum 
superoxide dismutase gene, useful for 
gene therapy, and for preparing 
Schistosoma vaccine, for selecting 
medicines, for preparing Schistosoma 
antibody, and for serological 
diagnosis 
Shanghai Human Gene Team Research 
Centre,Shanghai 201203,CN 
CN101748128A New Schistosoma japonicum titin 
gene, useful for gene therapy and for 
preparing schistosome vaccine, 
selecting drugs, preparing anti-
schistosome antibody, and 
serodiagnosis 
Shanghai Human Gene Team Research 
Centre,Shanghai 201203,CN 
CN101748127A New Schistosoma japonicum actin 
gene, useful for gene therapy and for 
preparing schistosome vaccine, 
selecting drugs, preparing anti-
schistosome antibody, and 
serodiagnosis 
Shanghai Human Gene Team Research 
Centre,Shanghai 201203,CN 
CN101747422A New fatty acid binding protein of 
Schistosoma japonicum, useful for 
preparing schistosoma vaccine and 
anti-schistosoma antibody, for 
selecting a medicament, and in 
serodiagnosis and gene therapy 
Shanghai Human Gene Team Research 
Centre,Shanghai 201203,CN 
CN101690806A New dendrimer-DNA vaccine, useful 
for preventing infection caused by 
Schistosomiasis japonica 
Southeast University,Wuxi, Jiangsu 
214064,CN | Jiangsu Institute for 
Bilharziasis Prevention and Control 
CN101671690B New recombinant expression carrier 
comprises Schistosoma japonicum 
gene, useful for preparing vaccine for 
preventing or treating schistosomiasis 
and for diagnosing schistosomiasis 
Shanghai Veterinary Research Institute 
CAAS,CN 
CN101671689A New recombinant expression carrier 
with Schistosoma japonicum gene, 
useful for preparing vaccine for 
preventing or treating 
schistosomiasis, and for preparing 
product for diagnosing 
schistosomiasis 
Shanghai Veterinary Research Institute 
CAAS,Shanghai 200241,CN 
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CN101624422B New recombinant poly-epitope 
antigen of Japanese schistosome, 
useful for preparing 
immunoprophylaxis vaccine of 
schistosomiasis japonica 
Shanghai Veterinary Research Institute 
CAAS,CN 
CN101555483B New polynucleotide encoding 
Echinococcus granulosus fatty acid 
binding protein (EgFABP)-Eg95 
polypeptide, useful for treating 
echinococcosis 
SUN YAT-SEN UNIVERSITY,CN | 
Institute for Parasitic Disease Chinese 
Center for Disease Control and 
Preventi,CN 
CN101524547A DNA vaccine useful for preventing 
and/or treating Cysticercus cellulosae 
infection, comprises eukaryotic 
expression vector and Cysticercus 
cellulosae antigen, e.g. Cysticercus 
cellulosae annexin gene 
PLA Second Military Medical 
University,Shanghai 200433,CN 
CN101434962B Eastern schistosomiasis tyrosine 
kinase conserved gene useful in 
preparing recombinant protein 
vaccine and DNA vaccine for 
preventing and controlling 
schistosomiasis 
Institute for Parasitic Disease Chinese 
Center for Disease Control and 
Preventi,CN 
CN101475938A New echinococcosis egG1Y162 
antigen gene obtained from 
Echinococcus granulosus, useful for 
preparing vaccine or diagnostic 
reagent for preventing and treating 
human or livestock echinococcosis 
Xinjiang Medical Univ.,Urumqi, 
Xinjiang 830054,CN 
CN101444622A New Japanese blood fluke gene 
recombinant live vaccine comprises a 
protective antigen gene of Japanese 
blood fluke and porcine pseudorabies 
virus, useful for inducing immune 
protection against Japanese blood 
fluke 
Military Veterinary Institute of Academy 
of Military Medical Sciences of Chinese 
People's Liberation Army,Changchun, 
Jilin 130062,CN 
CN101397558A Producing Schistosoma japonicum 
integral membrane tetraspanin 2 
(TSP2) fusion protein useful in 
preparing vaccine for 
schistosomiasis, by cloning and 
expressing Schistosoma japonicum 
TSP2 gene in Escherichia coli 
Chinese Academy of Agricultural 
Sciences Shanghai Institute of 
Veterinary,Shanghai 200232,CN 
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CN101270361B New extracellular cycle 2 gene 
encoding thrombospondins (TSPs) 
protein, useful for preparing a 
vaccine against Schistosoma 
japonicum 
SICHUAN UNIVERSITY,CN 
CN101050235A New Japanese schistosomiasis 
natural molecular vaccine candidate 
antigen comprises immature insect 
egg soluble antigen 66-68kDa 
molecule of Japanese blood fluke, 
used for reducing propagation of 
blood fluke egg 
WANG Shi-ping,Changsha, Hunan 
410078,CN 
CN100553683C Peptide-DNA bi-vaccine for anti-
inflection of schistosoma japonicum 
based on T-cell epitope 
UNIV NANJING MEDICAL 
CN1986797A Schistosoma japonicum tegument 
antigen gene, its encoding protein 
and its application 
Parasite Prevention Control Office China 
Disease Prevention Control Center | 
Shanghai Human Gene Group Research 
Center,Shanghai 201203,CN 
CN100394984C Bivalent DNA vaccine for Japanese 
blood fluke and preparation process 
thereof 
Huazhong University of Science and 
Technology 
CN100497627C Cloning of Japanese blood fluke 
vaccine antigen gene and its 
expression and application 
TIONAL INST PARASITIC DISEASES 
CHINESE CENT D | SHANGHAI 
HUMAN GENOME RES CENT 
CN1904053B Fusion gene of Japan schistosome 
antigen gene and constituted DNA 
vaccin and preparing process 
Huazhong University of Science & 
Technology,CN 
CN100528240C Preparation method and medicinal 
uses of Trichinella eelworm vaccine 
ZHANG X 
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CN100398155C DNA vaccine for preventing 
Haemonchus contortus disease of 
ruminant 
Nanjing Agricultural University 
CN100393357C Young schistosomiasis cell style 
vaccine for preventing from 
schistosomiasis disease 
UNIV CENT SOUTH,CN 
CN100335636C Thioredoxin gene of Schistosoma 
japonicum (Chinese Mainland 
Strain), useful in preparation of DNA 
vaccine for preventing and treating 
Schistosomiasis japonica 
China Disease Prevent and Cure Control 
Center Verminosis Prevent and Cure 
Control Office 
CN1749395A Cloning and expression of Japanese 
blood flukes SJCXSWL gene and 
DNA vaccine 
LU ZHIYUE 
CN1749394A Cloning and expression of HGPRT 
gene of Japanese blood fluke for 
preparation of DNA vaccine 
WANG SHIPING 
CN100374559C New protease subunit C3 of 
Clonorchis sinensis, and genes 
encoding it, for use in a diagnosis 
reagent kit, and for use in a vaccine 
UNIV ZHONGSHAN,CN 
CN100360665C New type I aldehyde dehydrogenase 
of clonorchis sinensis, for use in a 
diagnosis reagent kit and for use in a 
vaccine 
UNIV SUN YET-SEN,CN 
CN1670206A New protease subunit C7-I of 
Clonorchis sinensis for use in a 
diagnosis reagent kit, vaccine and 
pharmaceutical composition 
UNIV SUN YAT SEN 
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CN1670202A New microsome glutathione S-
transferase-1 of Clonorchis sinensis 
for use in a diagnosis reagent kit, 
vaccine and pharmaceutical 
composition 
UNIV SUN YAT SEN 
CN1670201A New fumaric reductase Ip subunit of 
liver fluke and polynucleotide 
encoding it, for use in a diagnosis 
reagent kit, and for use in a vaccine 
UNIV SUN YAT SEN 
CN1670200A New lactate dehydrogenase of 
clonorchis sinensis for use in a 
diagnosis reagent kit, vaccine and 
pharmaceutical composition 
UNIV SUN YAT SEN 
CN1670198A New thermostable type cytoplasm 
malic dehydrogenase of clonorchis 
sinensis for use in a diagnosis kit, 
and vaccine 
UNIV SUN YAT SEN 
CN1670197A New arginase of Japanese blood 
fluke, for use in a diagnosis reagent, 
vaccine and in a pharmaceutical 
composition 
UNIV SUN YAT SEN 
CN100389831C Gene engineering vaccine used for 
preventing pig cysticercosis and its 
preparation method 
China PLA Logistic PLA Nanjing 
Military Medicine Institute 
CN1272435C Gene of Chinese Mainland SJPP 
gene stock of japanese blood fluke, 
clone, expression and application 
Of Animal XUE Experiment | Shanghai 
Animal Biological Technology Research 
Centre | China Academy of Science 
Shanghai Livestock Verminosis 
Research Institute 
CN1511588A Japanese nucleic acid vaccine for 
blood fluke, comprises a eukaryotic 
expression vector and blood fluke 
antigen genes 
TONGJI MEDICAL COLLEGE 
CENTRAL 
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CN1249232C Schistosomiasis japonica (Chinese 
Continental strain) MFS4 gene clone, 
expression amd DNA vacine 
Shanghai Animal Biological Technology 
Research Centre,CN | Of Animal XUE 
Experiment,CN | China Academy of 
Science Shanghai Livestock Verminosis 
Research Institute,CN 
CN1100788C Peptide for vaccine of 
schistosomiasis 
UNIV BEIJING,CN 
CN1100787C Peptide for vaccine of 
schistosomiasis 
UNIV BEIJING,CN 
CN1100881C Nucleic acid vaccine for cysticercosis 
co-contracted by human and pig 
Second Military Medical University of 
PLA 
CN1052011C  Beijing Medical University,CN 
CN1061991C Schistosome vaccine peptide No.3 UNIV BEIJING MEDICAL,CN 
CN1068334C Schistosome vaccine peptide No.2 UNIV BEIJING MEDICAL,CN 
CN1061990C Schistosome vaccine peptide No.1 UNIV BEIJING MEDICAL,CN 
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CN1020797C  Beijing Solar Energy Institute 
IN201110079P1 Vaccine composition useful for 
preventing schistosomiasis comprises 
a full length cDNA of the large 
subunit of Schistosoma mansoni 
calpain cloned into a vector 
 
ZA201102008A Immunogenic formulation useful for 
protecting and/or treating an animal 
against a parasitic nematode, and for 
vaccinating a susceptible animal 
against infection from the parasitic 
nematode 
 
IN248555B New compositions comprising 
recombinant or synthetic antigens 
derived from hookworm, useful as a 
vaccine against hookworm infection, 
or for reducing hookworm size or 
reducing hookworm burden in a 
patient infected with hookworm 
 
IN201101367I4 Peptide immunogens of lymphatic 
filarial abundant larval transcript and 
lymphatic filarial vaccine 
composition comprising same 
 
IN201101366I4 Dominant T epitope of filarial 
transglutaminase and chimeric 
peptide vaccines for lymphatic 
filariasis 
 
IN241402B Constructing peptides based on three-
dimensional structure of homologs, 
useful as vaccines for protecting 
against helminth infections and for 
diagnosis 
 
IN200806261P4 New membrane protein Sm29, useful 
as vaccines for generating a 
protective immunity against 
infections caused by helminths, 
including Schistosoma and Fasciola, 
and for treating allergic diseases 
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IN200705429P4 Constructing peptides based on three-
dimensional structure of homologs, 
useful as vaccines for protecting 
against helminth infections and for 
diagnosis 
 
IN200402472P4 Constructing peptides based on three-
dimensional structure of homologs, 
useful as vaccines for protecting 
against helminth infections and for 
diagnosis 
 
IN200401050P1 New compositions comprising 
recombinant or synthetic antigens 
derived from hookworm, useful as a 
vaccine against hookworm infection, 
or for reducing hookworm size or 
reducing hookworm burden in a 
patient infected with hookworm 
 
UY28972A1  CARMONA CARLOS 
AU2002335061A8 New compositions comprising 
recombinant or synthetic antigens 
derived from hookworm, useful as a 
vaccine against hookworm infection, 
or for reducing hookworm size or 
reducing hookworm burden in a 
patient infected with hookworm 
 
IN200101455P4 Novel isolated cyst wall cysteine 
proteinase derived from Taenia 
solium useful as vaccine for treating 
cysticercosis or neurocysticercosis 
 
RU2205875C2 New Echinococcus granulosus 
poly:peptide antigen used to prepare 
vaccines for preventing infection by 
Echinococcus or Taeniid parasites 
UT LTD | UNIV OF MEL BURN | N JU 
ZILAND PASTEHREHL EHGRIKA 
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AU2002334119A1 New vaccines comprising a 64p 
protein, useful against infectious 
diseases borne by blood-sucking 
ectoparasites, e.g. malaria, dengue 
fever, yellow fever, arboviral 
encephalitides, lymphatic filariasis, 
plague or Lyme disease 
 
AU731026B2 Thiol proteases with Cathepsin L-
type activity useful in vaccine 
formulations against helminth 
parasites 
JOHN P DALTON 
AU200020764A Novel vaccine comprising helminth 
larvae and antihelmintic for 
providing non-pathogenic productive 
immunity against parasites in 
ruminants 
NEW ZEALAND MEAT RESEARCH 
& DE 
MX199810276A Vaccine for controlling infection by 
helminth parasites containing new 
peroxiredoxin or beta-tubulin, 
particularly used to combat liver 
fluke 
 
MX190278B Use of anti-helminth vaccines to 
control disease associated with loss 
of natural immunity esp. for control 
of periparturient rise of Haemonchus 
in sheep and of type II ostertagiasis 
 
NZ264575A Providing non-pathogenic immunity 
against parasites in ruminants by 
admin. of vaccine contg. helminth 
larvae followed by admin. of 
anthelmintic after 5-21 days 
NEW ZEALAND MEAT RESEARCH 
& DE 
RU2095082C1 Safe, effective anthelmintic vaccine 
contains conjugate of immuno-
stimulating carrier and protective 
protein antigen 
ATAULLAKHANOV RAVSHAN I | 
NEKRASOV ARKADIJ V | 
PUCHKOVA NATALYA G | PETROV 
REM V | KHAITOV RAKHIM M 
ZA199402410A Taenia ovis antigenic polypeptide 
used to develop vaccines to protect 
against infection by a cestode 
parasite, partic. in ruminants. 
PITMAN MOORE NEW ZEALAND 
LIMIT | PASTORAL AGRIC RES INST 
NZ LTD | UNIV MELBOURNE 
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EG19342A  NAT RESEARCH CENTER 
NZ245236A Protein complex parasitic nematode 
useful as an immunogen and 
anthelmintic agent in vaccine 
 
CS274305B1  LUKES STEPAN 
CS274304B1  LUKES STEPAN 
CS273807B1  LUKES STEPAN 
IL62142A Vaccine against Schistosomiasis 
prepd. by sonicating Schistosomiasis 
parasites 
YEDA RES & DEV 
NL255469B Non-living vaccines contng. antigens 
stimulating production in the host of 
antibodies and which give protection 
when injected against diseases 









Categories of Analysis  
 
Analysis is presented for the overall dataset (210 relevant families) as well as the four major 
relevant categories, Cestodes, Nematodes, Trematodes and nonspecific helminths.  The 
subcategories under each of these major headings were pooled together and analyzed as a group 
in order to present a large enough dataset for generating meaningful results. In most instances the 
data within the four groups was pooled together and analyzed as a group in order to present a 
large enough dataset for generating meaningful results. Platform technologies were not analyzed. 
 
ThemeScape Map of Derwent Data 
 
A graphical representation of the results was generated using ThemeScape, a tool within the 
Aureka platform initially developed by Aurigin Systems, Inc., and now available through 
Innovation.126  ThemeScape creates a virtual “map” of patent data by extracting keywords from 
the documents and plotting those topics in relation to one another.  “Islands” are formed by 
closely related topics and “mountains” are formed when a large number of documents all contain 
the same or similar keywords.  Gaps between distantly related topics represent an “ocean.”  
ThemeScape is a powerful tool which can reveal relationships within a large dataset that are not 
otherwise apparent. 
 
ThemeScape provides options for the sources of keywords within each document.  The maps 
presented below were derived from the DWPI title, DWPI abstract, and claims in English from 
one representative of each INPADOC family.  Extracting data only from representative 
documents prevents large patent families from skewing the results and gives equal weight to 
each invention.  Not all references had this DWPI data in their records, so the maps represent a 
subset of the entire datasets. 
 
The map in Figure 20 shows the topic found within the overall dataset of relevant documents. 
Many of the topics agree with the coding criteria. At the center left of the map is a series of 
mountains labeled with “Taenia Ovis, Serine Protease and Proenzyme” which represents the 
subunit vaccines category for the subgroup “Cestode”. This isolated grouping concurs with the 
patent documents analyzed as taenia document tended to refer only to taenia and not other types 
of helminths.127 
                                                
126 http://www.intellogist.com/wiki/Report:Thomson_Innovation/Viewing_Results/Analyzing_Results/ThemeScape.  
127 See US5618542A 
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At the center top and extending to the top right of the map contains a series of islands containing 
mountains labeled “Helminth, Ostergitae, Heartworm Onchocerciasis and Proteins Multivalent 
Proteins. This chain of mountains represents two unique categories, the first being the coding 
category of veterinary vaccines under the category of nematodes. Additionally this chain of 
mountains also represents subunit vaccines in regard to both veterinary vaccine for nematodes 
and also for vaccines to nematodes in general.   
The largest chain of islands extending from the center of the map to the bottom right represents 
both nematode vaccines as well as trematode vaccines as the labels “Nematode, Fasciola, 
Hookworm  and Schistosoma” are present. This chain of islands is related to both DNA vaccine 
technology and subunit vaccine technology. These different types of technology also related to 
both trematodes and nematodes. 
 
Figure 21.  ThemeScape map of the representative documents from 752 helminth vaccine and related technology 
documents. These documents collapsed to 207 family members out of the 210 documents. The dots on the map are 
assignees according to the legend below. 
Color Assignee 
  Moredun 







  Colorado state  
  Heska 




The Themescape map also indicates the involvement of different assignee in the various fields of 
technology. The distribution and clustering of the assignees into distinct islands and distinct 
mountains suggests that these top seven assignees are generally working in separate 
technological fields. 
 
In summary, the Themescape map illustrates the coding of the documents successfully placed the 
majority of the documents into correct subcategories as the labels on the peaks also correspond 
to the subcategories. These maps not only reveal the relationships between the different 
technologies in each group but they also validate the document coding protocol which is the 
basis for the further analytics presented below.  Additionally, the map suggests that each of the 
top seven assignees provided are involved in distinct areas of helminth vaccine and vaccine 
related technology.  
 
 
Priority Country v. Document Count 
 
Important questions to ask in the analysis of patent data is “where does the technology come 
from?” and “where is the technology being used?”  The first question can be answered by 
analyzing the priority country, which is the country in which the priority patent document is 
filed.  Further data can be gleaned from the country in which the top assignees are based, which 
is presented below.  The second question can be answered by analyzing the multi-jurisdictional 
filings, which also follows below. 
 
Although information regarding the priority country is useful, it does not necessarily indicate the 
source of the technology.  For example, publications HK1154041A0 and HK1156969A0 are 
assigned to Medicago, Inc., a Canadian company.  However, Medicago128 tends to file 
applications first in the U.S., and the priority documents for both of these references are U.S. 
applications.  Also, IN200503876P1 is assigned to a group of French entities - CNRS, the 
Pasteur Institute, and the University of Paris - but the priority document is a Canadian 
application.  Thus, some assignees file first in other jurisdictions, perhaps to take advantage of 
that country’s patent laws or because the patent will be practiced primarily in that country.  For 
example, Medicago has a manufacturing plant in the U.S., although its research facility is 
apparently in Canada.  
 
Most documents have priority data recoded in the Innovation database, but a few do not.  In the 
majority of cases, priority data can be found through patent family members.  When possible, 
priority information was added to the data.  Highlighted cells in the files presented in Appendices 
C and D indicate such manually corrected data. 
 
                                                
128 http://www.medicago.com/.  
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The priority country information for vaccine patent documents is presented in Figures 12 and 13.  
China is by far the largest source of priority documents.  The United States and Great Britain are 
secondary sources, followed by Russia, Brazil, Australia and New Zealand.  
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Figure 22.  The country from which 
an innovation represented by a 
relevant family member likely 
originated from. The determination 




Figure 23. Counties from which an  invention related to helminth vaccine technology originated. Countries shown 
in white have are not the origin of any Helminth vaccine technology amongst the 210 families.  Multijurisdictional 
agencies, such as WIPO and the EPO, are not indicated.   
 
 
Top Vaccine Families for Multi-Jurisdictional Filings 
 
Vaccine technologies that have been transferred to the most other countries were calculated by 
first determining the size of each INPADOC family within the vaccine document dataset.  This 
data may be slightly skewed because applications filed in certain jurisdictions are not recorded as 
being members of INPADOC families.129  These jurisdictions include Hong Kong, India, 
Mexico, the Philippines, Portugal, Taiwan, and Viet Nam.  For this reason, the TotalPatent 
Extended Family was also retrieved for each of the largest INPADOC families to try to capture 
family members from these jurisdictions.  It is still possible these jurisdictions remain under-
represented in the dataset.  The extended family was not retrieved for all documents because the 
export functions of TotalPatent do not allow this data to be captured in a convenient manner.  
The number of jurisdictional filings was determined by combining the INPADOC, DWPI, and 
TotalPatent families for each representative document. 
 
Twelve representative family members had INPADOC families with 10 or more members.  The 
top family was represented by RU2145876C1, an older document whose family already contains 
16 members.  The INPADOC family represented by RU2145876C1 has also been filed in 32 
different jurisdictions, which is the most of this group.  Two families are assigned to Merck and 
two to Biotech Australia . No other assignee is represented multiple times. The top ten families 
                                                
129 See also Notes on Patent Families in Appendix M. 
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according to filings in different jurisdictions are shown in Table III, and the details of each 
family can be found in Appendix E.	  
 
Table III.  Top Multi-Jurisdictional Filings per INPADOC Family. 
Publication 
Number 








US5942413A Biotech Australia 
PTY 
Limited,Roseville,A





AT, AU, CA, DE, DK, EP, ES, GR, JP, 
NZ, US, WO  
12 
US5871738A Biotech Australia 
Pty. 
Limited,Roseville,A





AT, AU, CA, DE, DK, EP, ES, GR, JP, 






AT, AU, CA, DE, DK, EP, ES, GB, JP, 




Dalton John Pius 
Blackrock Dublin IE 
AT, AU, BR, CA, CN, DE, EP, ES, GB, 
MX, NZ, US, WO 
13 
JP03103592B2 MUNN E A AT, AU, CA, DE, DK, EP, ES, GB, HK, 





 AT, AU, BR, CA, DE, EP, JP, NZ, TR, 
US, WO 
11 
RU2205875C2 UT LTD | N JU 
ZILAND 
PASTEHREHL 
EHGRIKA | UNIV 




DK173779B1 TRANSGENE SA AT, AU, CA, CN, DE, DK, ES, EP, FR, 
JP, PH, US,  
12 
DK703789T3 DALTON JOHN 
PIUS | ANDREWS 
STUART JOHN 
AT, AU, DE, DK, EP, ES, GB, GR, HU, 
JP, NZ, SI, US, WO ,ZA 
15 
MX190278B  AU, BR, DE, EP, ES, JP, MX, NO, NZ, 
RU, US, WO, ZA 
13 
 
Global Filing Trends for Helminth Vaccines 
 
The previous section assessed filing trends for individual family trends.  The relevant dataset was 
analyzed to determine the jurisdictions in which the entire vaccine population was filed.  The 
INPADOC and DWPI patent families were combined for each reference document, and each 
jurisdiction was counted only once per family.  For example, if a representative document had 
three European Patent Office applications, the EPO was counted once for that family.  The 
TotalPatent families were not incorporated into this dataset, due to the difficulties with exporting 
such data.  Thus, certain jurisdictions such as India, Taiwan and the Philippines may be under-
represented. 
 
Of over 230 possible different jurisdictions in which patent applications could potentially be 
filed, helminth vaccine families were filed in a total of 45 jurisdictions.  As shown in Figure 14, 
North America and Europe are popular locations for assignees to seek protection for inventions 
directed towards parasitic worms.  Of Asian countries, China, India, Japan, and Hong Kong were 
targets for filing. Australia and New Zealand also were targeted jurisdictions for filing.  
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However, Central and South America, other than Brazil, were poorly represented, and no filings 
were done in any African country other than South Africa.  Countries are only shown in Figure 
14 if at least one filing occurred in that country. 
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Figure 24.  Distribution of 
jurisdictional filings of the 210 
vaccine patent families.  This data is 









Figure 25.  Global filing trends by country.  The number of patent families that have sought protection in a given 
country are indicated by colors.  Countries shown in white have no identified filings among the 210 family 




The jurisdictions where each patent family chose to seek patent protect was also plotted on a 
world map (see Fig. 15, above).  Each jurisdiction is indicated once per family.  For example, if a 
given patent family filed three U.S. applications, the United States was counted once for that 
family.  Greenland was considered part of Denmark for this analysis.  Also, the former 
Yugoslavia was indicated under Serbia and Montenegro, the former Czechoslovakia under the 
Czech Republic, and the former Soviet Union under Russia.  Multijurisdictional agencies were 
not plotted.  Nearly 70% of patent families had filed PCT applications with WIPO, so excluding 
PCT filings probably did not skew the results, as each country was affected equally.  Also, since 
the map only indicates countries where PCT applications entered the national phase, the map 
gives a more accurate portrayal of the jurisdictions in which assignees are most interested.  
However, exclusion of filings at the European Patent Office (EPO), probably does leave some 
European countries slightly underrepresented on the map.  Other multijurisdictional agencies not 
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indicated on the map are the Eurasian Patent Office (EAPO)130 which consists of countries 
belonging to the former Soviet Union and in which 20 patent families filed, the African Regional 
Intellectual Property Organization (ARIPO)131 which currently represents 18 nations and in 
which seven patent families filed, and the Cooperation Council for the Arab States of the Gulf 
(GCC)132 which represents six nations on the Arabian peninsula and in which two patent families 
filed.   
 
The map demonstrates that the majority of patent families file in just a few countries.  The top 
nations for filings, indicated in red, are Australia, Canada, China, Japan, the Republic of Korea 
(South Korea), and the United States.  Secondary target nations, indicated in purple, are Brazil, 
Germany, India, Mexico, and New Zealand, followed by a group (in blue) that includes Austria, 
Norway, Russia, Spain, and South Africa.  A final group (in green) includes the Philippines, 
Vietnam, and several European nations.  No other nation had more than 20 patent family filings.  
Filings were particularly sparse in South America and Africa. 
 
Top Assignees by Patent Document Count 
 
Assignee data for patent documents is often inaccurate.  The patent rights could be sold to 
another assignee, who does not record the assignee.  Also, a company holding the rights changes 
its name or is sold in toto and new assignments are not recorded.  Some companies do not record 
an assignment until a patent is allowed, so published applications that are later abandoned or 
rejected do not have assignment data.  Outside of the U.S., university faculty members retain 
rights in their inventions so the name of the university is not given on the patent document.  
None of the patent databases maintain accurate updates for such changes or account for such 
missing data. 
 
Correction of patent assignee information must be performed manually.  While this represents a 
burden on clinic members’ time, such information would is invaluable to the use of the clinic 
report.  Accurate assignee information is essential in order for the report data to be updated, and 
so the correct owners of the technologies can be contacted for licensing inquiries. 
 
The main protocol for correcting assignee names is to use Google, searching for the company 
website or new releases about the company.  Business Week133 is a great source of information, 
as are technology-specific business reporters such as Fierce Biotech134.  These sources reveal the 
current accurate name of the company listed as the assignee or whether the company is now a 
wholly-owned subsidiary of a larger company. 
                                                
130 http://www.eapo.org/en/.  
131 http://www.aripo.org/.  
132 http://www.gcc-sg.org/eng/.  
133 http://www.businessweek.com/.  
134 http://www.fiercebiotech.com/.  
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If no information was readily obtainable, the assignee was searched using Innovation, restricting 
the date field to after the publishing date of the known document.  The Derwent Assignee field 
may have another assignee commonly listed with the company being researched.  A Google 
search of the two names together sometimes revealed a link between the two, such as a name 
change or an acquisition.  The Derwent assignee code135 is another source of assignee 
information.  Other companies may be linked to the same code, such as ASTR being used for 
both AstraZeneca and its acquired company MedImmune. 
 
If the only information available is the inventor name(s), then the document was located on 
Google Patent136.  This website has hyperlinks to other patent documents by the same inventor 
which may have assignee data recorded.  The name of the inventor was also searched on Google 
to find an association between the inventor and a particular company.  To make the search more 
accurate, the search includes both the inventor’s name and some keywords from the patent 
document.  LinkedIn137 and other networking websites are another source of information, and 
can be especially useful if an inventor is associated with multiple companies.  Typically the date 
of the application can be associated with a date range for when the inventor was working for one 
company rather than another.  Since patent applications can be filed months if not years after the 
date of the invention, this latter method was used with caution. 
 
Using the above methodology, the assignee information for each relevant document in the 
vaccine and supporting technologies categories was manually corrected as accurately as possible.  
The results were then sorted on assignee names to reveal the number of patent families 
associated with each assignee.  The two categories were analyzed together so a single list of 
assignees was generated, which is presented in Table IV. 
 
Table IV.  Assignees with the Most INPADOC Patent (210 Families). 
Standardized	  Assignee	   Number	  of	  families	   Home	  Country	  
Heska	   12	   U.S.A.	  
Merck	  &	  Co.	  	   9	   U.S.A.	  
Institut	  Pasteur	   7	   France	  
AusBiotech	   5	   Australia	  
Biotechnology	  and	  Biological	  Sciences	  





                                                
135 http://ip-science.thomsonreuters.com/support/patents/dwpiref/reftools/companycodes/lookup/. 
136 www.google.com/patents.  
137 http://www.linkedin.com.  
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Publication Year v. Patent Document Count 
 
Trends in publication of patent documents were analyzed for the entire dataset as well as for the 
three major categories, Cestodes Nematodes, and Trematodes. Non-distinguished patent 
documents were not charted due to the extremely low number of documents.  Publication date 
was chosen as the parameter for analysis, which indicates publication of applications generally 
18 months after filing and publication of patents after allowance.  In the few cases in which the 
publication date was not recorded, the year of publication could usually be found in DWPI data 
such as the DWPI update information. Additionally, the earliest published family member of an 
INPADOC family was used in this analysis as it would correlate with filing date of each families 
priority document.  
 
Figure 26.  Publication trends for patent families for the entire data set. The year of publication of each 
representative document of the 210 families is shown. 
 
The earliest representative family member was a U.S. patent issued in 1972, as shown in Figure 
16.  The second place document was published 8 years later in 1980.  From the early 1970’s until  
1980s it appears only two patents. After 1980, the rate of patent publications directed towards 
helminth vaccines increased from 1 ever 8 years to 1 to 2 documents ever year.  In the early 
1990’s the average number of publications leapt to roughly 5 publications a year, possibly 
because the TRIPS Agreement took effect in 1996 and patent applications began to be published 
18 months after filing.  The average number of filings per year remained around 5 until 2000 and 
onwards where the rate of publications began to steadily climb, up to 24 in 2012.  The number of 
publications in 2013 was approximately equal to 3. Considering this report includes a thorough 
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Figure 27.  Publication trends for patent families grouped into the category of Nematodes 
 
The earliest representative family member was a foreign patent issued in 1980. The second place 
document was published seven years later in 1987. Patent publication spiked in the late 1990’s-
early 2000’s and again starting around 2010. Seven patent family representatives were published 
in both 2011 and 2012. There has been nothing published for 2013. 
 
 
Figure 28.  Publication trends for patent families grouped into the category of Cestodes 
 
The earliest representative family members were three patents issued in 1991. The second place 
documents were published four years later in 1995. There were no patent documents from 1999-
2002. From 2003 to 2009 there was a steady trickle of patents published. Publications spiked in 
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2011 and 2012, with four cestode patent publications issued both years. There has been nothing 
published for 2013, yet. 
 
 
Figure 29.  Publication trends for patent families grouped into the category of Trematodes 
 
The earliest representative family member was a foreign patent issued in 1982. The second place 
document was published two years later in 1984. Patent publication spiked in the early 1990’s-
early 2000’s and again starting around 2010. One-hundred patent family representatives were 




Top IPC (Current) Classifications 
 
The International Patent Classification (IPC) system, established in 1971, is administrated by the 
World Intellectual Property Organization (WIPO).  The IPC “provides for a hierarchical system 
of language independent symbols for the classification of patents and utility models according to 
the different areas of technology to which they pertain.”138  The IPC contains eight core sections 
with approximately 70,000 subdivisions, called advanced levels.  WIPO continuously revises the 
IPC, with the core levels being updated every three years and the advance levels being reviewed 
a few times each year.  The current version of the core levels was released in 2012.   
 
The IPC (Current) codes were analyzed for each patent family.  Some families had more than 
one code, and each was counted. For the overall data set 15 codes represented 24 or more 
                                                
138 World Intellectual Property Organization, Preface to the International Patent Classification (IPC), WIPO IP 
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families. The top two codes were A61K 39/00 which contains medicinal preparations containing 
antigens or antibodies and C07K 14/435 which contains organic compounds from humans and 
from animals.. The definitions for the top 15 IPC families are provided in the table below. 
 
 
Figure 30.  Top IPC (Current) Classification of the entire relevant dataset of 210 relevant families. Each class 
represented at least 24 different families. 
 
Table IX. Definitions of the Top IPC (Current) Classifications of Vaccine Documents. 
A61K 39/00 123 Medicinal preparations containing antigens or antibodies 
C07K 14/435 68 Chemistry:Organic Chemisry: From Animals or From Humans 
A61K 48/00 46 
Medicinal preparations containing genetic material which is 
inserted into cells of the living body to treat genetic diseases 
123	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A61P 33/12 37 Anti-parasitic agent: Schistosomicides 
C07K 16/18 34  Immunoglobulins against material from animals or humans  
C12N 15/12 34 
 Mutation or Genetic engineering: Genes encoding animal 
proteins  
A61K 39/002 29 Medicinal Preparations containing Protozoa antigens  
C12N 1/21 27 
Micro-organism modified by introduction of foreign 
genetic material  
C12N 15/09 24 Mutation or genetic engineering: Recombinant DNA-technology 




















A search of the patent literature for publications containing keywords related to the helminth 
vaccines returned approximately 2,700 total documents representing almost 447 patent families. 
After examining the search results 210 of those patent documents related to the prophylactic 
helminth vaccines or for technologies that are used in the manufacture of vaccines.  Of those 
relevant documents, approximately 13% are specifically related cestodes, 30% were related to 
nematodes, 49% were related to cestodes with the remainder being non-specific. Thus, vaccine 
and vaccine related technologies are predominantly focused on nematodes and trematodes. This 
occurrence is not surprising as trematodes are highly prevalent in South-east Asian and 
nematodes readily infect both humans as well as livestock.  
 
However, filing of applications related to parasitic worms has been steadily increasing in the last 
decade, so there are likely many new technological advances that have yet to be fully tested in 
effectiveness against parasitic worms. 
 
Helminth vaccine technologies appear to originate from a small set of countries, mostly the 
United States, Great Britain, France, China, Brazil, Australia, and New Zealand.  Protection for 
helminth related intellectual property has been sought worldwide.  However, except for Brazil 
coverage in South America is quite minimal, and except for South Africa protection for these 
technologies is sparse in Africa. 
 
Top assignees for the relevant families were mostly large pharmaceutical companies, 
with the majority of patent families coming from Heska, followed by Merck, Institut Pastuer, 
AusBiotech, and Biotechnology and Biological Sciences Research Council. 
 
Progress is being made towards the development of an effective vaccine against 
helminthiases, but much work remains to be done, especially testing these novel vaccines under 
clinical conditions.  Additionally, this much-needed technology needs to be distributed to the 




APPENDIX A: Master Coding Spreadsheet (electronic version only). 
This Excel file contains a series of spreadsheets related to the coding of the representative 
documents from the 447 INPADOC family members found relevant from our searches. The first 
sheet contains the 447 family members, the category they were coded into indicated by color, 
and notes for the family members related to the basis of the coding decisions. The second, third, 
fourth, and fifth and sixth sheets are divided by categories, cestodes, nematodes, trematodes, 
nondistinguished and other. Each sheet contains the subcategories for each category and shows 
the subcategory where each family member was placed.  
Table 4. Indicating the color used for coding family members into specific categories 





















































































APPENDIX B: Full Records of Relevant Family Members (electronic version only). 
This Excel file contains detailed information of each of the 210 relevant patent family member.  
The full records, containing all available information extracted from Thomson Innovation, are 
given for each representative family member.  Documents are organized alphabetically by 
publication number. 
APPENDIX C: Full Records of all Relevant Documents (electronic version only). 
This Excel file has detailed information of each relevant patent document. The full records, 
containing all available information extracted from Thomson Innovation, are given for each 
document.  Documents are organized alphabetically by publication number. 
Trematodes	   Nondistinguished	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APPENDIX D: Top Multi-Jurisdictional Filings Spreadsheet (electronic version only). 
This Excel file has representative family members ranked according the size (number of 
publications) of the INPADOC family each document represents.  The top 21 largest families are 
then analyzed based on the total number of jurisdictions in which each family has been filed.  
Data is assembled from INPADOC, DWPI and TotalPatent family data.   
APPENDIX E:  Assignees Analysis Spreadsheet (electronic version only). 
Assignee data for each representative family member was manually corrected to reflect changing 
company names or the acquisition of an assignee by another company.  This Excel file details 
assignee data first by publication number, and then assignees are shown by total number of 
families believed to be owned by that assignee.  All relevant family members were pooled 
together to generate an assignee list covering all highly relevant documents.  The website for 
each assignee is also given, if possible. 
APPENDIX F: Priority Document Spreadsheet (electronic version only). 
This Excel file has representative family members marked according to the earliest priority 
document of each INPADOC family. Data is assembled from INPADOC, DWPI and TotalPatent 
family data. The determinations is made from a combination of both TI’s recommendation as 
well as by an analysis given by the team member examining the priority document.    
Appendix G: PDF Files of Representative Patent Documents (electronic version only). 
This folder contains the pdf files for each representative family member, if available. Note that in 
a few instances a pdf file of the representative family member was not available.  Thus these 
folders do not contain the complete number of representative documents. 
Appendix H: PDF Files of Selected Non-Patent Literature (electronic version only). 
This folder contains pdf files for selected non-patent literature relevant to helminth vaccines.  An 
extensive search of NPL was not performed; rather the documents included in this folder are 
mostly review articles which reveal the general state of the art, summarize available 
technologies, or discuss strategic approaches to immunization.   
Appendix I: Keywords Used in Searching. 
The following represents the keywords used by the team members in patent database searching.  
Note that each team member used different combinations of these terms, and only a subset of 
terms was used for any particular search. 
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Echinococcus granulosus,  
Echinococcus multilocularis,  
E. vogeli,  
E. oligarthrus 



















 Opisthorchis felineus,  
Clonorchis sinensis 
Paragonimus westermani;  
Paragonimus africanus; 
Paragonimus caliensis;  
Paragonimus kellicotti 

































Trichinella spiralis,  
Trichinella britovi, 
 Trichinella nelsoni, 
Trichinella nativa 
Wuchereria bancrofti 




• Parasitic Worm 





o Helminth (mess with root extenders with this one) 
o Schistosom* 
o Endoparasit* 











o Dehelminthisation (dehelminthization?) 
 
• Vaccine 
o Immun! (TP) Immun* (TI) 
o Immunologic! Immunologic*  
o Immunostimul! or immuno-stimul!  
o Immunomodul! or immuno-modul! 
o Immunologentic 
o Immunogen! Immunogen* 
o Immuniz! Immuniz 
o Vaccin! (TP) Vaccin* (TI) 
o Virotherap! Virotherap* 
o Prophyl! Prophyl* 
o  Antigen! Antigen* 
! Epitope! Epitope* 
! Determinant 
o Antiinfective or anti-infective (sp?) 
o Antiviral or anti-viral or anti viral 
o Viricide or Virucide 





Appendix J: Notes on Patent Families. 
 
If there are several applications or publications for an individual invention (in other countries) 
claiming the same priority or priorities and originating from the same inventors, those documents 
constitute a “patent family.”  All of the family members are related to one another by common 
priority publications with associated priority dates.  INPADOC families are organized solely on 
priority data, whereas DWPI families focus on the inventions such that divisional applications of 
a single priority document are considered to be in different patent families.  Further, Lexis 
TotalPatent reports “extended families” which are similar to INPADOC families but include 
more jurisdictions. 
 
The concept of the patent family first emerged through the Paris Convention on the Protection of 
Intellectual Property in 1883, while automated systems enabling patent family searching became 
available through the establishment of the IIB in The Hague in 1947and INPADOC in Vienna in 
1972.  Since then, patent searching has evolved due to exponential improvements in computing 
and communication technology. 
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The term patent family can be defined in a number of ways depending on the relationship 
between a patent document and its priority or priorities within the meaning of the Paris 
Convention.  The differences only become obvious when the structure of a patent application is 
complex, i.e. when applications are filed in several countries.  Such applications may cite various 
earlier applications as priorities, or the different patent offices involved in the grant process may 
accept or refuse different patent claims.  This results in patents which have different scopes of 
protection. 
 
An important point when using any database to retrieve information on patent families is that 
there is never any guarantee that you will find all the corresponding patent documents that exist.  
Database producers do what they can to ensure completeness, but they can never guarantee it.”139 
 
The “Extended” (INPADOC) Patent Family 
 
“The biobibliographic and legal status databases form the basis of the EPO’s raw data resources 
(INPADOC).  In February 2008 the bibliographic data included about 60 million bibliographic 
data sets from almost 80 different countries.  The legal status database contains a collection of 
more than 50 million legal events from 48 countries. 
 
From the beginning, the concept was to cover as many countries and as many publication levels 
as possible.  One of the strongest motives for the integration of INPADOC into the EPO was the 
wish to combine the particular strengths of INPADOC with the EPO’s existing in-house 
bibliographic database, “DOC-DB.” 
 
Following integration of the two databases in the 1990s, the raw data behind both databases is 
now the same.  And since esp@cenet draws on the same pool of data as raw data resources 
(INPADOC) and DOC-DB, it contains the same documentation. 
 
However, the philosophy of the “extended” (INPADOC) patent family is quite different, and so 
are the results of family searches.  Unlike the “also published as” feature in esp@cenet, which 
only shows “equivalents,” i.e. almost identical documents, an INPADOC family search should 
retrieve all documents relating in any way to the root document. 
 
Features of INPADOC 
 
When using INPADOC via one of the commercial database host services, it bears all the 
esp@cenet features, plus the following: 
 
                                                
139 EUROPEAN PATENT OFFICE, Patent Families (Feb. 29, 2008), http://www.epo.org/patents/patent-
information/about/families.html. 
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• Standardization of applicant and inventor names 
• References to abstracts from Chemical Abstracts and Thomson Scientific 
Abstracts are made within the patent family 
• By including the legal status database additional information is available and 
additional family links can be established 
• National application numbers, international application numbers and domestic 
relations are included in the family search 
 
For both of the EPO’s raw data resources (INPADOC) and esp@cenet, even where no priority 
has been claimed by the patent application, artificial or “intellectual” links are built in systematic 
way for the complete PCT minimum documentation.  The same is done for older documents 
(pre-1968) for which the priority information is not complete. 
 
Definition of the “extended” (INPADOC) patent family 
 
All the documents directly or indirectly linked via a priority document belong to one patent 









Document D1 Priority P1   
Document D2 Priority P1 Priority P2  
Document D3 Priority P1 Priority P2  
Document D4  Priority P2 Priority P3 
Document D5   Priority P5 
 
As mentioned above, national patent application numbers, international application numbers and 
domestic relations are included in the family search. 
 
In the “extended” (INPADOC) patent family, it does not matter where a search is started.  It can 
be an application number, a priority application number or a publication number. 
If the search starts with a publication number, all application numbers, domestic application 
numbers, priority numbers and international application numbers are used to retrieve additional 
documents.  For all documents found in this step, step one is repeated.  This iteration process 
ends only when no more new documents can be found. 
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Raw data resources (INPADOC) also use some additional sophisticated rules for certain 
countries, for example, if publication numbers are used instead of priority numbers in the 
original documents.  This happened rather frequently for older documents, where the priority 
claims were not treated as carefully as they are now.  The inclusion of legal status information in 
the patent search also sometimes retrieves additional links, e.g. for divisional applications, 
continuations, continuations in part or national publications of first filings of PCT (international) 
applications, where the priority links are often missing. 
 
Limitations of the family search in raw data resources (INPADOC) have to rely on the 
correctness of the data supplied by the co-operating patent offices and the extent to which it is up 
to date.  In particular, delays in the delivery of bibliographic data can vary significantly 
depending on the country concerned and the time period covered.  Before relying on the 
completeness of a patent family, users should check where there are gaps or delays in certain 
areas.  This kind of information can be found in the PFS and PRS statistics on the internet, which 
are updated weekly and contain indications of missing or delayed document series.  See raw data 
resources (INPADOC) useful tables and statistics.  To be absolutely sure about the actual status 
of a patent, users are recommended to contact the appropriate patent issuing authority direct.  
Particular care has to be taken in the case of European patents which have entered into the 
national phase.  The completeness and accuracy of data can vary significantly from country to 
country.  A good overview of the volume and kind of "post-grant" information available in raw 
data resources (INPADOC) can be found in the raw data resources (INPADOC) FAQ.  For most 
of the EPO member states, information about the validation, lapse, etc., of European patents is 
given as part of the legal status information, and as mentioned before is less consistent due to the 
different quality of data available.  Starting from week 50/2007, additional post-grant 
information is taken from the fee administration system and included in the legal status part of 
the database.  
 
Thomson Scientific WPI Patent Family (DWPI)  
 
“Patent Families in the Thomson Scientific World Patents Index (WPI) draw together patents 
covering the same invention.  Their relationship is defined by the priority or application details 
claimed by each document.  Thus, in its simplest form, a new document (D1) claiming a unique 
priority (P1) will be assigned to be the basis of its own, new patent family in Thomson Scientific 
WPI.  
 
Subsequently, if a second document (D2) also claiming priority P1 is received by Thomson 
Scientific this will be added (as an ―equivalentǁ‖) to the patent family already containing 
document D1.  Other documents claiming priority P1 will also be added to this family as 
―equivalents as they are included in the database.  Thus, a patent family may contain anything 
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from a single document to 10 or more.  Each patent family represents a single record in the 
Thomson Scientific WPI database.  
 
The basic document is the first member of a patent family that appears in Thomson Scientific 
WPI, so it may not necessarily be the first one published for that invention. Differences in the 
speed that patenting authorities supply data to Thomson Scientific and in the processing time for 
documents from different countries may affect which document appears in Thomson Scientific 
WPI first and becomes basic. 
 
Patents often claim more than a single priority and these must match before any equivalent is 
added to a family.  This means that if a basic document (D3) claims priorities P2, P3 & P4, a 
subsequent document (D4) claiming priorities P2 & P3 will be added to the family as an 
equivalent, whereas patent D5 which claims priorities P2, P3 and a unique priority (P5) will form 
the basis of a new, but related patent family.  In cases such as this, the accession number of any 
related family is included in the cross-reference field of each relevant Thomson Scientific WPI 
record. 
 
Divisions and continuation patents maintain the same status as the original specification.  This 
means that if GB1 is a basic, and GB2 is divisional to GB1, then GB2 will also be a basic (in its 
own family).  However, if GB1 is equivalent to another document already in the Thomson 
Scientific WPI database, then GB2 will also join this family as an equivalent.  It should be noted 
that family relationships will be defined by the order in which patents appear in Thomson 
Scientific WPI.  
 
Thomson Scientific also puts a lot of resources into including patents in families even when no 
foreign priority is claimed, e.g. when an application has been made beyond the 12 months 
defined by the Paris Convention.  Thomson Scientific identifies these "non-convention" 
equivalents by the presence of foreign nationals and addresses in the Inventor field in the 
absence of priority data other than the local filing details.  Equivalency is determined through a 
time-consuming manual check of inventors, subject matter, etc.  
 
In this way Thomson Scientific attempts to make patent families in Thomson Scientific PI as 
comprehensive as possible.  However, because of the incidence of multiple priorities, and patent 
divisions and continuations (especially continuing applications in US documents), it is important 
to retrieve all related families through their common priorities in order to have a comprehensive 




                                                
140 Id. 
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Appendix K:  PDF Files of This Report (electronic version only). 
 
This folder contains separate pdf files of this report and the cover to the report.  The ITTI Clinic 
wishes for this report to be as widely disseminated as possible, so that all interested parties may 
have access to the information presented herein.  However, anyone is free to base a subsequent 
report on our work as long as proper attribution is given to ITTI. 
 
 
 
